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Abstract 
 
Equine laminitis manifests as a painful condition of the foot and is 
characterised by disruption of the dermo-epidermal lamellar bond within the equine 
hoof. Chronic pain in laminitis leads to debilitation and if unchecked euthanasia of 
the horse and is therefore a significant welfare issue for horses worlwide. P2X 
receptors are shown to have a pivotal role in pain pathways as well as other tissue 
functions making them attractive candidates for research in naturally occurring 
diseases such as equine laminitis. 
In this study, the presence and distribution of P2X receptors in tissues of the 
equine digit and its associated vasculature and innervation was investigated. The 
investigation was extended to tissues from horses suffering from naturally occurring 
chronic active lamintis in an attempt to identify changes in distribution or expression 
of the receptors in these tissues. Finally, the functionality of the P2X receptors 
expressed in equine nervous tissue was investigated. 
Gene expression (mRNA) for all seven receptors was found in the studied 
tissues and protein expression for P2X1-3 and 7 receptor subtype proteins in these 
tissues was confirmed with Western blot analysis. Immunohistochemical analysis of 
P2X1-3 and 7 receptor subtypes distribution showed differential cellular distribution 
within normal equine tissue and differential distribution and expression between 
normal and diseased tissues too. In particular, in a horse with shorter duration of 
chronic laminitis (1 month), P2X3 receptor subtype immunostaining in DRG neurons 
presented a marked increase in large neurons which coincided with a decrease in the 
proportion of these neurons in the DRG. Also, horses suffering from chronic 
laminitis displayed expression of P2X3 receptor subtype in smooth muscle cells of 
the palmar digital artery which was absent in normal horses. In chronic laminitic 
hooves, P2X7 receptor subtype showed particularly strong staining in partially 
keratinised cells. Finally, intracellular calcium measurements provided evidence for 
the presence of functional purinergic and P2X receptors in equine spinal cord and 
DRG cells, respectively. 
The expression of P2X receptor subtypes in key equine tissues for laminitis 
and chronic pain in laminitis and their differential expression in laminitic tissues 
highlights a potential role in chronic laminitis molecular mechanisms. Further 
research in this area may provide insights into putative targets for disease modulation 
and pain management in chronic laminitis and other conditions of the horse 
associated with chronic pain. 
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1.1 Laminitis 
 
Laminitis is a systemic disease of the horse that manifests as a painful 
condition of the foot characterized by disruption of the dermo-epidermal lamellar 
bond within the equine hoof (Hood 1999a, Jones et al. 2007). It is a major problem in 
the horse, not limited to any specific breed, occupation or geographical region, and is 
accompanied by severe pain, prolonged chronic course and in its most severe form 
can culminate in euthanasia (Slater et al. 1995, Hampson et al. 2012). 
Laminitis is not a new condition, having been recognised for over 2000 years 
(Harris 2012), but it continues to be responsible for dysfunction and disruption in the 
working life of many horses (Hampson et al. 2012). The general prevalence of 
laminitis is difficult to estimate due to variation in the design of epidemiological 
studies. Differences in the definition of a “case” and in the population sets included 
in studies can account for the variability in laminitis prevalence reported in literature. 
In Australia, a prevalence of laminitis of 23.8% is reported (Buckley et al. 2007), 
whereas in Great Britain, recent data record a lower prevalence of 0.5-17.1% 
(Menzies-Gow et al. 2010, Wylie et al. 2013). This is due to a pony club population 
used by Buckley et al. (2007), which is likely to target more susceptible breeds, and 
to the inclusion of chronic inactive cases too. On the other hand, in the study by 
Wylie et al. (2013) the reporting process relied upon veterinary surgeons to report 
cases, which led to underreporting, and cases included only acute and not recurrent 
laminitis. 
Furthermore, horses affected with laminitis can progress to develop severe or 
chronic lameness and debilitation. In the UK, Menzies-Gow et al. (2010) report that 
33.7% of the animals diagnosed with laminitis presented with repeated episodes. In 
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addition, annual economical losses associated with the evaluation, treatment and loss 
of horses after a diagnosis of laminitis are estimated to be at least $13 million (Moore 
2009). Thus, the prevalence of laminitis among horses, impacts on the welfare of 
horses, and the economic and emotional costs have a significant impact on horse 
owners. 
 
 
1.1.1 Hoof anatomy 
 
The equine hoof is unique in that a single digit on each limb supports the 
entire weight of the animal and withstands a considerate biomechanical load (Pollitt 
1994). The digit is suspended in the heavily keratinised hoof capsule by an 
interdigiting lamellar architecture which helps reduce stress and ensures even energy 
transfer during peak loading of the equine foot. The innermost layer of the hoof wall, 
stratum lamellatum, bears up to 550-600 primary epidermal lamellae which project 
from its surface in parallel rows facing the outer surface of the distal phalanx. Along 
the length of each primary epidermal lamellae (PEL) are an extra 150-200 secondary 
epidermal lamellae (SEL) also orientated towards the distal phalanx. The epidermal 
lamellae are lined with a layer of epidermal basal cells (Pollitt 1998) (Figure 1.1 and 
1.2a). 
Beneath the hoof wall is the highly vascular and sensitive corium or dermis 
which consists of a dense matrix of tough connective tissue containing a network of 
arteries, veins and capillaries and sensory and vasomotor nerves. The corium 
provides the hoof with nourishment and bears primary and secondary dermal 
lamellae (PDL, SDL) which interlock with the epidermal lamellae to form the 
4 
suspensory apparatus of the distal phalanx (SADP). On the other end, the deep 
surface of the corium blends with the periosteum of the distal phalanx to suspend the 
phalanx in the hoof capsule (Pollitt 1992) (Figure 1.1). 
At the interface of the epidermis and the dermis is the basement membrane, a 
tough, unbroken sheet of extracellular matrix (Figure 1.1 and 1.2b). The basement 
membrane attaches the basal cells of the lamellar epidermis on one side and the fine 
connective tissue fibrils emanating from the dorsal surface of the distal phalanx on 
the other (Pollitt 1998). The epidermal basal cells are firmly attached to the basement 
membrane with hemidesmosomes and anchoring filaments (French & Pollitt 2004b). 
Basement membrane changes is one of the earliest pathological events to occur in 
laminitis and could be the event that initiates the collapse of the lamellar architecture 
(Visser & Pollitt 2011). 
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Figure 1.1. Schematic of the suspensory apparatus of the distal phalanx. The primary 
and secondary epidermal and dermal lamellae interlock to form the SADP. At the 
interface is the basement membrane and basal epidermal cells. The corium contains a 
network of arteries, veins and capillaries and at its deep surface blends with the 
periosteum of the distal phalanx. 
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Figure 1.2. Histology of the equine hoof dermo-epidermal junction. (a) PEL and SEL 
interlocking with the PDL and SDL. The epidermal lamellae are lined with a layer of 
epidermal cells. Capillaries are present in the SDL, H&E stain. (b) At the interface of 
the epidermis and the dermis is the basement membrane attached to the basal cells of 
the epidermis (asterisk), Periodic acid Schiff’s stain. 
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1.1.2 Phases of laminitis 
 
The progression of laminitis can be divided into three phases, the 
developmental, acute, and chronic phase. The developmental phase is the period 
between the initial causative insult and the first appearance of clinical signs 
associated with laminitis. During this period the horse might be showing signs of the 
inciting event but the actual developmental phase is relatively asymptomatic making 
it difficult to recognise (Hood 1999b). By the time foot pain is apparent lamellar 
pathology is underway (Pollitt 2004b). Research around the pathogenesis of laminitis 
has focused on the developmental phase in an attempt to identify trigger factors of 
the condition and targets for intervention (Bailey et al. 2009, Budak et al. 2009, de 
Laat et al. 2013). 
The acute phase begins with the onset of clinical foot pain (Hood 1999b). 
Clinical signs during this phase can include a change in stance and gait with 
continually shifting weight from one foot to another and lameness, digital pain, 
bounding digital pulse, and warm feet (Swanson 1999). Treatment strategies in the 
acute phase focus on analgesia and digital support, as well as resolving any 
underlying causes triggering the disease (inflammatory diseases, endocrinopathic 
diseases, etc) (Hood 1999d). 
After the acute phase, the horse can make an apparent complete recovery or 
progress into the chronic phase (Pollitt 2004b). Chronic laminitis has a broad 
spectrum of clinical presentations, ranging from mild lameness and capable of 
significant athletic function, to fluctuating episodes of disease, through to severe 
chronic pain necessitating euthanasia on humane grounds (Morgan et al. 1999). 
Furthermore, chronic phase laminitis can be further categorised in early chronic 
8 
laminitis, where there are no morphological changes to the hoof capsule, chronic 
stable laminitis, where there are morphological changes to the hoof capsule but the 
horse is clinically improving, and chronic active laminitis, where the distal phalanx 
remains unstable and which is usually accompanied by severe pain (Morgan et al. 
1999, Stashak 2002, Parks & Mair 2009) (Figure 1.3). 
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Figure 1.3. Sagittal section of a normal equine hoof (a) and a hoof from a horse 
suffering from chronic laminitis (b). In the chronic laminitic hoof rotation of the 
distal phalanx in the hoof capsule is apparent (arrow). 
 
10 
1.1.3 Laminitis aetiopathogenesis 
 
While the precise aetiology of laminitis remains obscure it is clear that its 
pathogenesis is multifactorial in nature (Robertson et al. 2009) The mechanisms 
involved in the pathogenesis of laminitis are probably numerous and interrelated, and 
may represent different events in the complex time course of laminitis rather than 
individual pathogenetic mechanisms. However, laminitis cases can be categorised 
based on main aetiology to facilitate their study.  
 
 
1.1.3.1 Inflammatory laminitis  
 
Inflammatory laminitis includes cases with inflammation as a main cause, 
such as systemic diseases, especially gastrointestinal disease, but also endometritis, 
and grain overload. The black walnut- and the carbohydrate overload-induced 
laminitis models also fall into this category. 
The prodromal stages of laminitis are associated with alterations in lamellar 
vascular function (Peroni et al. 2005) with the presence of warm feet and a bounding 
digital pulse in the acute phase suggesting a vascular component is active in laminitis 
(Hood et al. 1993). Vascular events could lead to loss of lamellar tissue function as a 
result of a complex cascade of events initiated by ischaemia. Primary events in this 
cascade are necrosis due to anoxia followed by reperfusion injury with peroxidation 
of cellular and intracellular lipids secondary to the production of superoxide radicals 
(Hood et al. 1993). Evaluation of digital perfusion in laminitis developmental and 
acute phases has yielded conflicting data and correlation and interpretation of these 
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data is difficult because of the different experimental designs used in each study 
(Pollitt & Davies 1998, Hood et al. 2001). However, several studies, using both the 
black walnut- and the carbohydrate-induced laminitis model, report an early decrease 
in lamellar microvascular blood flow detected during the developmental phase of 
laminitis followed by reperfusion prior to onset of clinical signs (Galey et al. 1990, 
Hood et al. 1993, Adair et al. 2000, Hood et al. 2001). These observations support an 
ischaemia/reperfusion mechanism of injury for equine laminitis similar to the one 
seen in Raynaud’s syndrome in human (Hood et al. 1990). 
The initial ischaemic insult may be a result of digital vasospasm, which may 
be locally induced or may be influenced by circulating vasoactive amines released 
from the gastrointestinal tract (Elliot et al. 2003, Bailey et al. 2004, Elliot & Bailey 
2006, Noschka et al. 2009), especially with the equine lamellar dermis showing a 
predisposition for venoconstriction (Peroni et al. 2006). Ischaemia could also be a 
result of altered blood flow bypassing lamellar capillaries through arterio-venous 
anastomoses (Hood et al. 1993, Moore et al. 2004) and may explain equivocal data 
around hoof wall surface temperature changes (Moore et al. 2004). Other vascular 
events participating in the development of laminitis include increased postcapillary 
resistance and possible lamellar oedema (Eaton et al. 1995), damage to the vascular 
endothelium and endothelial cells dysfunction with increased presence of endothelin-
1 (ET-1), activation of leukocytes, haemorrheologic dysfunctions and coagulopathies 
with platelet activation and subsequent release of vasoactive mediators, such as 5-
hydroxytryptamine (5-HT) and thromboxane A2, which are all consistent with 
impaired local perfusion (Hood et al. 1993, Weiss et al. 1994, Weiss et al. 1995, 
Katwa et al. 1999, Elliot et al. 2003, Bailey et al. 2004, Eades et al. 2007, Loftus et 
al. 2007). 
12 
Furthermore, enzymatic events following the haematogenous delivery of 
‘laminitis trigger factors’ to the hoof could also participate in the disruption in 
lamellar ultrastructure and ultimately dermo-epidermal separation. The enzymatic 
events include activation of matrix metalloproteinases (MMPs) which causes 
breakdown of basement membrane collagen and laminin and anchoring filaments 
(Pollitt 1996, French & Pollitt 2004a). MMPs exist in lamellar hoof where they 
participate with TIMPs (tissue inhibitors of MMPs) in the cellular reorganisation 
required for hoof wall growth and wound repair (Pollitt et al. 2003). MMP synthesis 
may be stimulated by pro-inflammatory cytokines during endotoxaemia (Johnson et 
al. 1998) or other gut-derived trigger factors such as streptococcal exotoxins and 
bacterial thermolysin (Mungall et al. 2001). 
Studies in tissues from laminitic horses (developmental, acute, and chronic 
phase) revealed MMP-2 and MMP-9 activity to be substantially greater than in 
normal horses (Johnson et al. 1998, Pollitt et al. 1998). It was thus suggested that 
inadvertent and uncontrollable lamellar MMP activation during laminitis 
developmental phase could be responsible for the dermo-epidermal separation which 
characterises laminitis (Pollitt et al. 1998, Pollitt et al. 2003). However, a later study 
found a large variation in the concentrations of lamellar MMPs in laminitic (both 
experimentally induced and naturally acquired laminitis) and non-laminitic horses 
and could not confirm a correlation of MMP activity with catalytic activity at the 
basement membrane (Loftus et al. 2009). Furthermore, in lamellar samples of early 
developmental laminitis, MMP-9 was found to be largely present in its inactive form 
while MMP-2 activation occurred more than 12 hours after basement membrane 
degradation (Visser & Pollitt 2012). 
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Another protease, ADAMTS-4, has been found upregulated in the 
developmental phase of carbohydrate overload-induced laminitis and in naturally 
acquired laminitis (Budak et al. 2009, Coyne et al. 2009). MMP-14, a protease active 
at the dermal-epidermal interface participating in membrane surface proteolytic 
events, has also been found upregulated in acute laminitis (Kyaw-Tanner et al. 2008). 
Activation of MMP-2 and MMP-9 is, therefore, likely to be secondary to the primary 
event leading to lameness, and the role of other proteases, including MMP-14 and 
ADAMTSs, needs to be considered (Kyaw-Tanner et al. 2008, Visser & Pollitt 
2012). 
 
 
1.1.3.2 Endocrinopathic laminitis 
 
Endocrinopathic laminitis is defined as laminitis developing from putative 
hormonal influences rather than pro-inflammatory and intestinal conditions (Johnson 
et al. 2004). Conditions associated with endocrinopathic laminitis include Equine 
Cushing’s Syndrome, Insulin Resistance (or Equine Metabolic Syndrome or Pasture-
Associated Laminitis) and iatrogenic corticosteroid administration. In common to all 
these conditions are disturbed glucose and insulin regulation, and, most importantly, 
the development of insulin resistance (McGowan 2008). This category also includes 
the insulin-induced laminitis model. 
Insulin resistance has been identified as a major predisposing condition for 
laminitis (Treiber et al. 2006b) and prolonged hyperinsulinaemia alone has been 
shown to induce laminitis in healthy ponies and horses, demonstrating that laminitis 
can be triggered by insulin (Asplin et al. 2007, de Laat et al. 2010). The mechanisms 
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linking insulin resistance or hyperinsulinaemia and the development of laminitis 
include glucose uptake impairment, and vascular and pro-inflammatory effects 
(Treiber et al. 2006a). 
It has been proposed that changes in glucose metabolism and reduced glucose 
availability to insulin-sensitive cells secondary to insulin resistance could lead to the 
development of laminitis pathology. The normal equine hoof has been shown to have 
a high glucose consumption and glucose deprivation induces dermo-epidermal 
separation in hoof explants in vitro by reduction of hemidesmosomes numbers and 
basal cell cytoskeleton collapse (Pass et al. 1998, French & Pollitt 2004b, Wattle & 
Pollitt 2004). However, recent data suggest glucose uptake in the hoof is insulin-
independent and supporting this, mRNA expression of the insulin-independent 
glucose transport protein GLUT1 was strong in lamellar tissue whereas mRNA 
expression of the insulin-dependent glucose transport protein GLUT4 was absent or 
barely detectable. Laminitis in insulin resistant horses is therefore unlikely to be the 
result of glucose deprivation (Asplin et al. 2011). 
Insulin resistance is also associated with vascular effects, such as 
vasoconstriction and endothelial damage which are found in laminitis (Treiber et al. 
2006a). Under insulin-resistant conditions, impairment of the phosphatidylinositol 
(PI3) kinase pathway and endothelial production of the vasodilator agent NO, and 
reduced capillary perfusion are noted (Potenza et al. 2009, Venugopal et al. 2011). 
Also, increased levels of ET-1 have been found in laminitic lamellar tissue and 
hyperinsulinemia is known to increase secretion of ET-1 from the endothelium 
through the mitogen-activated protein (MAP) kinase pathway and enhace ET-1 
activity promoting vasoconstriction (Katwa et al. 1999, Potenza et al. 2009, 
Venugopal et al. 2011). 
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Furthermore, the presence of insulin resistance is linked to a pro-
inflammatory state with circulating cytokines which can contribute to the 
development laminitis (Dandona et al. 2004, Belknap et al. 2007). Finally, insulin 
itself, without the presence of an insulin resistance associated pro-inflammatory 
state, can induce MMP-9 protein levels via the MAP kinase pathway and contribute 
to the development of endocrinopathic laminitis (Fischoeder et al. 2007, de Laat et 
al. 2011). 
 
 
1.1.3.3 Weight-bearing laminitis 
 
Laminitis can also occur as a result of mechanical overload situations and is a 
relatively common complication in conditions that cause prolonged excessive 
unilateral weight-bearing in a limb (support limb laminitis) (Redden 2004, Virgin et 
al. 2011). Support limb laminitis could be a result of direct mechanical overload of 
the suspensory apparatus of the distal phalanx or reduced digital blood flow caused 
by a lack of normal cyclic loading and inadequate perfusion of the lamellar tissue 
followed by potential activation of enzymatic and chemical mediators (van Eps et al. 
2010). 
 
 
1.1.4 Pain in laminitis 
 
Pain is the main clinical feature in laminitis and it is the inability to manage 
the unrelenting and severe pain associated with the disease that is the most common 
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cause of euthanasia in laminitic horses (Collins et al. 2010a). Pain first becomes 
evident at the beginning of the acute phase of laminitis where it manifests as a result 
of lamellar pathology. In the acute phase of laminitis pain is nociceptive, secondary 
to actual tissue damage or tissue-damaging stimuli, and inflammatory, with presence 
of hypersensitivity arising from the interaction of inflammatory mediators with 
neurons, and can disappear after full resolution of the disease (Kidd & Urban 2001, 
Nicholson 2006, Collins et al. 2010a). However, in the chronic phase of laminitis, the 
chronic pain state that can develop has a neuropathic component to it and often 
persists after resolution of the initiating pathology (Jones et al. 2007, Collins et al. 
2010a). 
 
 
1.1.5 Chronic pain in laminitis 
 
Chronic pain in laminitis is difficult to treat and is the main reason for 
euthanasia in laminitic horses making pain in laminitis a pathologic entity in itself 
rather than just a sign. 
Pain management in laminitis has traditionally consisted predominantly of 
anti-inflammatory drug administration (Rietmann et al. 2004). This approach, 
however, has failed to control pain in chronic laminitic cases and revealed its 
multifactorial nature (Driessen et al. 2010). The mechanisms responsible for the 
development of chronic pain in laminitis are not completely clear but they include 
events occurring secondary to inflammation (inflammatory component) and nerve 
injury (neuropathic component), both locally in the hoof and centrally in the CNS 
(Yaksh 2010). 
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Inflammatory mediators participate in chronic pain by direct stimulation of 
nociceptors or by producing many and complex changes in afferent nerve fibres 
ranging from overt activation or sensitisation to other stimuli to alterations in the 
phenotype and structure of sensory nerves (Dray 1995). In chronic laminitis, plasma 
concentrations of the pro-inflammatory cytokine TNF-α, a critical factor in 
neuropathic pain, and lamellar concentrations of inflammatory mediators IL-1 and 
IL-6 are elevated and are thought to play an important role in chronic laminitic pain 
(Treiber et al. 2009, Leung & Cahill 2010, Steelman et al. 2013). 
Nerve injury has also been reported in laminitis with tearing of the dermo-
epidermal lamellar bond resulting in widespread injury to C and Aδ fibres in the 
dermal layers (Morgan et al. 1999, Driessen et al. 2010). As a consequence of nerve 
damage, both injured and uninjured axons exhibit abnormal activity including 
dysregulated gene expression and generation of ectopic discharges leading to the 
amplification of the response to noxious stimuli as part of peripheral hyperalgesia 
(Marchand et al. 2005). Peripheral nerve morphology is also altered in digital nerves 
and reduced numbers of unmyelinated and myelinated fibres are noted compared to 
normal horses. However, changes are not limited to peripheral nerves, as increased 
expression of the neuronal injury marker, activating transcription factor-3 (ATF3), 
and neuropeptide Y (NPY) has been found in C8 dorsal root ganglia (DRG) neurons 
(innervating the hoof). These changes are similar to those reported in other 
neuropathic pain states providing evidence for a neuropathic component in the pain 
state in chronic laminitis (Jones et al. 2007). DRG neurons of chronic laminitic 
horses have also been shown to strongly express the ionophore protein α2δ, which in 
rodent pain models is increased in states of hyperalgesia and allodynia (Collins et al. 
2010a). Furthermore, in other species, neuropathic pain is also driven by spinal and 
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supraspinal mechanisms (Ossipov et al. 2000). Ongoing activity in injured nerves 
triggers central sensitisation with involvement of synaptic modulators and excitatory 
amino acids, alterations in ion channel kinetics and properties, increased density of 
ionotropic receptors and activation of kinases pre- and post-synaptically (Constigan 
et al. 2009). 
Finally, other local events are also thought to contribute to the pain state in 
chronic laminitis. Extensive bone modelling and endosteal oedema have been 
observed in the distal phalanx of chronic laminitic horses presenting with unrelenting 
foot pain supporting the presence of increased intraosseous pressure, known to 
trigger persistent pain (Lemperg & Arnoldi 1978, Morrisset et al. 1999, Collins et al. 
2010a). Another important factor for pain may be digital ischaemia following 
vasoconstriction in response to inflammatory mediators, arterio-venous blood 
shunting, thrombosis, and compression of the vascular bed (Hood et al. 1994, 
Grosenbaugh et al. 1999, Morgan et al. 1999). Similarly, increased pressure within 
the hoof capsule as a result of distal phalanx displacement, oedema that accompanies 
inflammation or haemorrhage, and dilation of hoof vessels in response to 
neuropeptides (eg. CGRP) from activated sensory nerve terminals may exacerbate 
foot pain in chronic laminitis (Hood et al. 1999c, Morgan et al. 1999, Driessen et al. 
2010). 
Effective pain management in horses with laminitis therefore favours a multi-
modal approach that involves a combination of drugs with different pharmacologic 
mechanisms of action and different target sites within the somatosensory neural 
conduit (Dutton et al. 2009, Driessen et al. 2010, Guedes et al. 2012). 
 
 
19 
1.2 Purinergic P2X receptor biology 
 
1.2.1 Adenosine 5’-triphosphate (ATP) 
 
Adenosine 5’-triphosphate (ATP) has a fundamental intracellular role as the 
universal source of energy in all living cells. In addition to being an intracellular 
energy source, ATP has now also been recognised as an extracellular signalling 
molecule (Drury & Szent-Györgyi 1929, Bodin & Burnstock 2001b). 
Drury and Szent-Györgyi in 1929 were the first to report extracellular purine 
actions. They noted extracellular adenosine had a negative chronotropic effect on the 
heart, a vasodilatory effect on arteries and inhibited intestinal movements (Drury & 
Szent-Györgyi 1929). Several studies followed showing the extracellular actions of 
ATP in the nervous system and ATP release from sensory nerves (Feldberg & Hebb 
1948, Holton 1959). But it was not until 1972 that a complete purinergic 
neurotransmission hypothesis was developed (Burnstock 1972). Since then, ATP 
signalling has been reported in the nervous system, epithelial cells, the immune 
system and a plethora of other systems where it participates in physiological and 
pathological processes (Fields & Stevens 2000, Vonend et al. 2002, Schwiebert & 
Zsembery 2003, Mounkaïla et al. 2005, Bours et al. 2006). 
 
 
1.2.2 Extracellular ATP release 
 
Following cell membrane damage or necrosis, all cells can potentially release 
ATP into the extracellular environment, which might be important in triggering 
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cellular responses to trauma (Fields & Stevens 2000, Cook & McCleskey 2002). In 
addition, numerous neuronal and non-neuronal cells can release ATP in a controlled 
manner as part of a physiological mechanism. 
In the peripheral and central nervous system, ATP functions as a 
neurotransmitter and is often co-transmitted with other neurotransmitters. ATP has 
also a special role in neuronal-glial and glial-glial signalling and is an important 
gliotransmitter (Abbracchio et al. 2009). In non-neuronal cells, ATP can be released 
as a result of mechanical stimulation, such as shear stress, cell swelling, or 
mechanical distension, but also other stimuli such as hypoxia, acidosis, and agonist 
stimulation (Bodin & Burnstock 2001a, Knight et al. 2002, van der Wijk et al. 2003, 
Gourine et al. 2005, Orriss et al. 2009, Praetorius & Leipziger 2009, Tu et al. 2010). 
Finally, spontaneous nucleotide release has been noted in renal epithelia, which 
appears to provide a tonic signalling input to the cells (Geyti et al. 2008). 
ATP release occurs mainly through (i) cytolysis with cell membrane damage 
or necrosis following physical or biological trauma, (ii) transport via a conductive 
pore or transporter such as connexins, volume-regulated Cl- channels, the cystic 
fibrosis transmembrane conductance regulator (CFTR) and P2X7 receptor itself, and 
(iii) exocytotic release both by neuronal and non-neuronal cells (Cotrina et al. 1998, 
Bodin & Burnstock 2001a, Schwiebert & Zsembery 2003, Praetorius & Leipziger 
2009, Tu et al. 2010). 
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1.2.3 Classification of purinergic receptors 
 
Purinergic receptors (also known as purinoceptors) are divided into two 
classes, P1 or adenosine receptors and P2 purinoceptors recognising primarily ATP, 
ADP, UTP, and UDP. P2 receptors are further subdivided into two subclasses, P2X 
receptors which are ligand-gated ion channels and P2Y receptors which are G 
protein-coupled receptors (Burnstock & Kennedy 1985, Ralevic & Burnstock 1998). 
 
 
1.2.4 P2X receptor structure and properties 
 
P2X receptors are classical cationic ligand-operated channels that upon ATP 
binding open the pore permeable to Na+, K+ and Ca2+ (Ralevic & Burnstock 1998). 
Each receptor is made of three individual subunits arranged in a “head-to-tail” order 
(Egan et al. 2006) (Figure 1.4a). P2X subunits are encoded by seven distinct genes, 
P2X1-P2X7 (North 2002). Individual subunits have intracellular amino- and 
carboxy-termini, a large extracellular loop, and two hydrophobic transmembrane 
segments, TM1 and TM2 (Egan et al. 2006) (Figure 1.4b). The extracellular loop 
contains the ATP binding pocket, binding sites for agonists, antagonists and 
modulators, and additional structure elements that influence the receptor’s 
deactivation and desensitisation rates (Vial et al. 2004, Li et al. 2008). Gating 
properties of the ion channel by agonist vary dramatically with receptor subtype, 
with P2X2, P2X4, and P2X7 homomeric channels showing slow desensitisation and 
P2X1 and P2X3 channels exhibiting rapid activation and desensitisation (North 
2002). The extracellular loop also contains cysteine residues, some of which 
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participate in disulfide bond formation and likely define the tertiary structure of the 
protein (Vial et al. 2004). The P2X receptor TM regions are thought to form the 
central ion conduction pore and participate in the conformational changes during 
receptor activation (North 2002, Egan et al. 2006). P2X subunits can assemble to 
form either homomeric or heteromeric receptors. Diversity of the P2X receptors 
phenotypes is yielded by different subunit combinations and the receptors’ functional 
and pharmacological properties are directly determined by their subunit composition 
(Torres et al. 1999). 
Activation of P2X receptors by ATP results in a momentary increase in the 
free concentration of intracellular calcium and thus, initiation of cell functions (Egan 
et al. 2006, Li et al. 2008). The intracellular calcium accumulation is achieved in two 
distinct ways. First, P2X mediate a membrane depolarization that opens voltage-
dependent Ca2+ channels. Second, the receptor itself is permeable to Ca2+ and cations 
travel through the channel into the cell (Egan et al. 2006). Also, during prolonged 
agonist application, P2X2, P2X4 and P2X7 receptor channel is reported to 
progressively dilate to provide a permeation pathway to molecules with a molecular 
weight of up to ~900 Da; a process termed cell permeabilisation (Virginio et al. 
1999, Dunn et al. 2001, North 2002, Yan et al. 2008). 
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Figure 1.4. (a) P2X receptor structure (Abbracchio et al. 2009, reproduced with 
permission). (b) P2X protein domains. 
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1.2.5 P2X receptors agonists and antagonists 
 
The development of subtype-specific agonists for P2X receptors is difficult 
and therefore not many are available. In Table 1.1 are summarised some widely used 
P2X agonists and antagonists and their specificity. 
 
Table 1.1. Widely used P2X receptors agonists and antagonists and their specificity. 
 Specificity References 
P2X agonists   
αβ-meATP and 
βγ-meATP 
P2X receptors, higher potency for 
P2X1 and P2X3 receptors 
Dunn et al. 2001, 
Coddou et al. 2011 
ATPγS P2X receptors except P2X7 
receptors and several P2Y receptors 
Watano et al. 2004 
2-meSATP P2X and P2Y receptors Coddou et al. 2011 
BzATP potent for P2X7 receptors Baraldi et al. 2004 
   
P2X antagonists   
Suramin P2X and other purinergic receptors Dunn & Blakeley 1988 
PPADS P2X1, P2X2, P2X3, P2X5, and 
P2Y1 receptors 
weak or ineffective against P2X4, 
P2X6, and P2X7 receptors 
Connolly 1995 
Jacques-Silva et al. 2004 
Iso-PPADS P2X receptors, potency may be 
species-dependent 
Connolly 1995, 
North 2002 
TNP-ATP P2X1, P2X3, and P2X2/3 receptors Thomas et al. 1998, 
Virginio et al. 1998 
Oxidised ATP potent for P2X7 receptors Wiley et al. 1994 
KN-62, KN-04 potent for P2X7 receptors Gargett & Wiley 1997 
BBR P2X7 receptors Jiang et al. 2000 
A-317491 P2X3-containing receptors Jarvis et al. 2002 
 
25 
1.2.6 P2X1-7 receptor subtypes distribution 
 
Since 1994, when the first P2X receptor was cloned from rat cDNA (Valera 
et al. 1994), P2X receptors have been identified in many vertebrates, in virtually all 
mammalian tissues, mediating a large variety of responses, from fast transmission at 
central synapses, contraction of smooth muscle cells, and macrophage activation to 
proliferation and cell death (reviews Burnstock & Knight 2004, Burnstock & 
Verkhratsky 2009). 
Although, P2X receptors have been found to be widely distributed, they are 
also specifically distributed among different tissues in the vertebrate body (North 
2002). 
P2X1 receptor subtype was originally cloned from rat vas deferans smooth 
muscle and although it has been found in other cells (e.g. neurons and platelets) it is 
most highly expressed in smooth muscle cells of various organs, such as vessels, and 
urinary bladder, where it participates in smooth muscle contraction (Valera et al. 
1994, Clifford et al. 1998, Nori et al. 1998, Petruska et al. 2000, Vial & Evans 2000). 
P2X2 receptor subtype is found in sensory neurons in homomeric receptors or 
co-localised with P2X3 subunits where they contribute to nociceptive responses and 
chemosensory and mechanosensory transduction (Prasad et al. 2001, Zhong et al. 
2001, Wang & Neuhuber 2003, Cockayne et al. 2005). P2X2 channel is also 
expressed in epithelial cells where it may affect functions such as vesicle trafficking, 
protein secretion and signal-transduction pathways (Taylor et al. 1999, Glass et al. 
2000). 
P2X3 receptor subtype was originally cloned from rat DRG cDNA (Chen et 
al. 1995) and is consistently located in neuronal cells (Bradbury et al. 1998) with 
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functional studies using P2X3 knockout mouse lines confirming an important role of 
the P2X3 channel in nociceptive signalling (Cockayne et al. 2000, Souslova et al. 
2000). 
P2X4 receptor subtype, on the contrary, appears to have a very wide 
distribution pattern which includes the central and peripheral nervous systems, 
skeletal and smooth muscle, epithelial and endothelial cells, to only name a few (Bo 
et al. 2003, Kaczmarek-Hajek et al. 2012). Attention, however, has been drawn to its 
expression in microglia and implication in the pathogenesis of neuropathic pain 
(Tsuda et al. 2003). 
P2X5 receptor subtype has been predominently found in the central nervous 
system and the immune system, but is also associated with cell differentiation of 
epithelial and other cells (Lê et al. 1997, Gröschel-Stewart et al. 1999a, Gröschel-
Stewart et al. 1999b, Hoebertz et al. 2003). 
P2X6 receptor subtype is predominant in skeletal muscle, widespread in the 
central and peripheral nervous systems where it overlaps to a large extent the 
expression pattern of P2X4 and P2X2 subtypes and can also be found in epithelial 
cells often together with the P2X4 subtype (Collo et al. 1996, Nawa et al. 1998, 
Glass et al. 2000, Turner et al. 2003). 
Finally, P2X7 receptor subtype is expressed in most cell types, including 
haematopoietic cells, different types of glial cells in the central and peripheral 
nervous system, epithelial cells, bone cells, and others (Collo et al. 1997, Gröschel-
Stewart et al. 1999a, Gartland et al. 2001, Zhang et al. 2005). P2X7 channel 
contributes to inflammatory responses and the development of chronic inflammatory 
and neuropathic pain but also mediates apoptosis in various cells types (Schulze-
Lohoff et al. 1998, Gröschel-Stewart et al. 1999a, Solle et al. 2001, Labasi et al. 
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2002, Chessell et al. 2005, Kong et al. 2005). Differences in P2X receptor subtype 
expression within and between tissue types appear to therefore allow for tissue- and 
zonal-specific response to extracellular ATP release. 
 
 
1.2.7 P2X receptors in pain pathways 
 
Since ATP was first found to induce pain, research focused on identifying 
P2X receptor subtypes involved in pain pathways, their localization in the nervous 
system and their potential role and regulation in physiological and pathological pain 
states. P2X3 and P2X2/3 receptors, in particular, have a major role in pain 
mechanisms (Jarvis 2003). P2X3 and P2X2/3 receptors are upregulated in sensory 
neurons in different chronic pain models and functional studies confirm an important 
role for these receptors in nociception (Cockayne et al. 2000, Souslova et al. 2000, 
Jarvis et al. 2002, Ueno et al. 2003, Pan et al. 2009). At peripheral and spinal sites, 
P2X3 and P2X2/3 receptors have been shown to play a crucial role facilitating pain 
transmission whereas at supraspinal sites they are thought to have an inhibitory role 
(Jarvis 2003, Fukui et al. 2006) (Figure 1.5). 
P2X4 receptors are normally expressed in small amounts in the microglia of 
the central nervous system (CNS) and are not involved in acute pain behaviour in 
physiological pain states. However, in cases of nerve injury an upregulation of P2X4 
receptor subtype is noted in activated microglia of the spinal cord and activation of 
the receptors has been indicated to be not only necessary but also sufficient for 
causing allodynia (Tsuda et al. 2003). Like P2X4 receptor subtype, P2X7 receptors 
are modulating pain transmission through indirect mechanisms and not direct 
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neuronal activation (Donnelly-Roberts & Jarvis 2007). P2X7 receptors have been 
identified in microglia, astrocytes, satellite and Schwann cells and are thought to be 
involved in abnormal pain sensation and development and maintenance of 
neuropathic pain (North 2002, Chessell et al. 2005, Donnelly-Roberts & Jarvis 
2007). Other receptors, such as P2X4/6 or P2X1/5 or P2X2, P2X4, and P2X6 
subtypes identified centrally have also been suggested to participate in pain pathways 
(Chizh & Illes 2001, Nakatsuka & Gu 2006) (Figure 1.5). Finally, the existence of a 
natively expressed heteromeric P2X4/7 receptor subtype has been reported in bone 
marrow-derived macrophages and a potential integrative mechanism of the 
nociceptive roles of both P2X4 and P2X7 receptors in chronic pain states has been 
suggested (Guo et al. 2007). 
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Figure 1.5. Ascending control of pain and localization of pain relevant P2X receptors 
in both neuronal and non-neuronal cells along the neuraxis (Wirkner et al. 2007, 
reproduced with permission). 
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1.3 P2X receptors in equine laminitis - Hypothesis 
 
Purinergic signalling has been demonstrated to have an important role in 
across tissue systems and P2X and P2Y receptors participate in the regulation of 
many functions. Here, the investigation of P2X receptor expression in equine tissue 
was chosen as they have key roles in functions such as neurotransmission and 
chronic pain but also autocrine loops of endothelial and epithelial cells making them 
an interest target for study in a multifactorial condition such as laminitis. Also, more 
data and tools are available for P2X receptors compared to P2Y receptors making 
their study in a species like Equids more accessible. However, P2Y receptor 
expression in Equids may also present an interest and future work should include the 
study of their expression too. 
 
In nociception, P2X2 and P2X3 receptors have an important role (Jarvis 
2003) with P2X3 and P2X2/3 knockout mice exhibiting a reduction in pain sensation 
(Cockayne et al. 2000, Cockayne et al. 2005). P2X4 and P2X7 receptors expressed in 
glia are also involved in abnormal pain sensation (Tsuda et al. 2003, Chessell et al. 
2005) (see 1.2.7 P2X receptors in pain pathways). Therefore, their study in horses 
could reveal important targets for pain therapeutics in chronic laminitic pain for 
which no effective treatments are available. 
Also, vasoconstriction and its role in the development of laminitis and 
chronic laminitis is an important part of laminitis research (Hood et al. 1993, Moore 
et al. 2004) and purinergic regulation of vascular tone, with a particular role for 
P2X1 receptors expressed in smooth muscle (Burnstock 2009) may advance research 
in this area. Hypoxia and glucose deprivation, which may develop in lamellar tissues 
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during laminitis vascular events, are also known to trigger purinergic signalling 
(Cavaliere et al. 2001). Moreover, cycles of hypoxia and reoxygenation have been 
suggested as a pathogenetic mechanism behing vascular events in laminitis (Hood et 
al. 1993) and recent work has revealed altered purinergic signalling with increased 
P2X1 receptor expression to occur following cycles of hypoxia-glucopenia and 
reoxygenation (Elliott et al. 2013).  
Additionally, P2X5 and P2X7 receptors have been shown to participate in the 
early differentiation, terminal differentiation, and death of human keratinocytes 
(Greig et al. 2003), and therefore present an interest in the study of the events leading 
to dyskeratosis in laminitis. Moreover, the observed dyskeratosis in laminitic hooves 
has been suggested to occur secondary to aberrant insulin signalling via the MAP 
kinase pathway (Asplin et al. 2010). This may further implicate P2X receptors as 
MAP kinase signalling is one of the known downstream pathways following 
activation of the receptors (Donelly-Roberts et al. 2004, Seino et al. 2006). 
Furthermore, P2X7 receptor has a pivotal role in apoptosis (Schulze-Lohoff et al. 
1998, Kong et al. 2005) and investigation of P2X7 receptor expression in epidermal 
basal cells may give an insight in the increased apoptosis rates in epidermal basal 
cells present in laminitic hooves (Faleiros et al. 2004, Asplin et al. 2010). P2X7 
receptor is also involved in purinergic signalling in response to mechanical stimuli 
and in mechanically stimulated bone remodelling (Li et al. 2005, Panupithu et al. 
2008) and may participate in the pathogenesis of mechanical overload lamintis but 
also in the events occurring in the hoof following increased pressure in the hoof 
capsule after the development of laminitis and bone remodelling in chronic laminitis. 
Finally, P2X receptors may be implicated in the enzymatic events occurring 
in laminitis. P2X7 receptor has been found to mediate the release of proteases, such 
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as ADAMTSs and MMP-9 (Gu & Wiley 2006, Arandjelovic et al. 2012), which are 
elevated in lamellar tissue in inflammatory laminitis (Kyaw-Tanner et al. 2008, 
Visser & Pollitt 2012), supporting a role for P2X receptors in the enzymatic events 
occuring in inflammatory laminitis. In endocrinopathic laminitis, insulin itself can 
induce MMP-9 protein levels (de Laat et al. 2011) via insulin receptor activation and 
altered MAP kinase signalling (Fischoeder et al. 2007) possibly involving P2X 
receptor signalling (Donelly-Roberts et al. 2004, Seino et al. 2006). 
 
Since purinergic signalling may have an important role in laminitis 
pathogenesis and development, investigation of P2X receptors expression in equine 
tissues related to laminitis could provide a better understanding of ongoing changes 
occurring during laminitis and P2X antagonists may be a useful tool for disease 
modulation.  
 
 
1.4 Aims 
 
The aims of this study are: 
1. To identify the presence of P2X receptors in equine tissue 
2. To characterise the distribution of P2X receptors in the equine hoof and its 
associated vasculature and innervation 
3. To identify changes in expression and distribution of P2X receptors in the 
equine hoof and associated vasculature and innervation in horses suffering 
from chronic laminitis 
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4. To investigate the functionality of the P2X receptors expressed in equine 
nervous tissue and characterise them pharmacologically 
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Chapter 2 
 
Materials and Methods 
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2.1 Samples 
 
Equine tissue samples were collected with owner consent immediately post 
mortem from euthanized horses in accordance with institutional ethical approval. 
Animals included horses that had no previous history or evidence of fore limb or 
neurological disease and horses in a chronic active stage of laminitis (in accordance 
with Pollitt & Collins 2011). Sampled tissues included palmar digital artery (a. 
digitalis lateralis/medialis), palmar digital vein (v. digitalis lateralis/medialis), 
palmar digital nerve (n. digitalis palmaris lateralis/medialis), hoof, ipsilateral C8 
DRG and spinal cord (forming median nerve (n. medianus) which innervates the 
hoof), ipsilateral C4 DRG and spinal cord (not innervating the hoof). 
 
Palmar digital artery, vein, and nerve 
The palmar digital neurovascular bundle was located on the side of the 
pastern, the palmar digital artery, vein and nerve were identified and a ~3 cm long 
segment was dissected from each (Figure 2.1a). 
 
Hoof 
The hoof was removed and samples, comprising of hoof wall and corium, 
were taken from the middle aspect of the dorsal hoof (adapted from Pollitt 1996). 
Briefly, hooves were cleaned, and with the sole on the base plate of the band saw, the 
first cut was in a lateral to medial direction palmar to the processus extensorius of 
P3. Subsequentally, cuts were made sagittally on either side of the hoof midline, 1 
cm apart. With the newly cut surface on the base plate the remaining tissue block 
was trimmed to remove the bulk of the outer hoof wall and all but the dorsal cortex 
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of the distal phalanx. Finally, four transverse cuts, ~0.5 cm apart, were made starting 
below the coronary band and ending before the tip of P3 to obtain the samples, and a 
scalpel was used to excise excess hoof wall and the dorsal cortex of the distal 
phalanx from the samples (Figure 2.1b and c, and 2.2). 
 
C4 and C8 DRG and spinal cord segments 
The vertebral column from C2 to the T1 was dissected out and the spinal cord 
was exposed with a longitudinal cut on the contralateral side of the side of interest 
just abaxial to the spinal processes effectuated with the help of a band saw. Once the 
spinal cord was exposed, C4 and C8 spinal segments were located and transected 
with a scalpel. The respective DRGs were then located in the intraspinal space and a 
cut to the spinal nerve distal to the DRG was made to dissect out the spinal cord 
segment with the attached DRG. Finally, the DRG and spinal cord segments were 
separated and excess tissue was removed with a scalpel (Figure 2.1d, e, and f). 
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Figure 2.1. Equine sampled tissues. (a) Skin incision on the side of the pastern 
revealing the palmar digital neurovascular bundle (arrow). (b) Sagittal section of a 
normal hoof. The insert shows a hoof sample before trimming excess hoof wall and 
the distal phalanx bone. (c) Sagittal section of a hoof from a chronic laminitic horse 
with obvious rotation and sinking of P3 (arrow). (d) Use of the band saw for a 
longitudinal cut of the vertebral column to expose the spinal cord. (e) Longitudinal 
section of the vertebral column exposing the spinal cord. (f) C4 spinal cord with 
respective DRG (arrow) before separation. 
38 
 
 
 
 
 
 
 
 
Figure 2.2. Band saw protocol carried out for the collection of hoof samples (adapted 
from Pollitt 1996). 
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2.2 Molecular biology experiments 
 
2.2.1 RNA extraction 
 
Samples for mRNA signal detection were collected in RNAlater (Applied 
Biosystems) and stored at -80 oC until they were processed for RNA extraction. For 
RNA extraction, tissue samples were weighed and homogenised in TRI Reagent 
(Applied Biosystems) (150 mg tissue/1 mL TRI Reagent). Briefly, the weighed tissue 
was diced and placed in liquid nitrogen along with a dismembrator chamber and ball. 
Once frozen, the diced tissue was placed in the chamber with the ball and 
homogenised at 2000 rpm for 45 seconds (Mikro-Dismembrator U, B.Braun Biotech 
International). In case the homogenisation was incomplete, the chamber and its 
content were placed back in liquid nitrogen and the dismembration cycle was 
repeated until the tissue was fully homogenised. The homogenised tissue was then 
placed in TRI Reagent. 
TRI Reagent suspensions were vortexed and left at room temperature (RT) 
for 30 minutes before centrifugation at 12,000 g at 2-8 oC for 10 minutes. The 
supernatant was collected in a new eppendorf tube and chloroform (200 µL/1 mL 
TRI Reagent) was added to the suspension. The tube was then shaken vigorously by 
hand for 15 seconds and left at RT for 2-3 minutes before centrifugation at 12,000 g 
at 2-8 oC for 15 minutes. The colourless aqueous upper phase containing RNA (400 
µL/1 mL TRI Reagent) was transferred to a new eppendorf tube. Total RNA was 
isolated with the RNeasy® Mini Kit (Qiagen) according to the manufacturer’s 
instructions. Briefly, an equal volume of 70% ethanol in DEPC treated water was 
added to the collected aqueous phase and mixed by pipetting. 700 µL of the sample 
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was transferred to an RNeasy spin column and centrifuged at 10,000 rpm (RT) for 15 
seconds. The flow-through was discarded and the step was repeated with the 
remaining sample. Buffer RW1 (350 µL) was added to the RNeasy spin column, the 
column was centrifuged at 10,000 rpm for 15 seconds and the flow-through 
discarded. At this stage, a DNase digestion step (RNase-free DNase set, Qiagen) was 
performed to remove possible traces of genomic DNA from the samples. In a new 
eppendorf tube DNase I stock solution (10 µL/sample) was added to Buffer RDD (70 
µL/sample) and the solution was mixed by gently inverting the tube. The DNase 
incubation mix (80 µL) was added directly to the RNeasy spin column membrane 
and the column was left at RT for 15 minutes. Buffer RW1 (350 µL) was then added 
to the RNeasy spin column, the column was centrifuged at 10,000 rpm for 15 
seconds and the flow-through discarded. The RNA isolation protocol was continued 
with Buffer RPE wash steps. More specifically, Buffer RPE (500 µL) was added to 
the RNeasy spin column and centrifuged at 10,000 rpm for 15 seconds. The flow-
through was discarded and the step was repeated with a 2 minutes centrifugation. 
The RNeasy spin column was placed in a new collection tube, centrifuged at full 
speed for 1 minute, and then placed in a new 1.5 mL eppendorf tube. RNase-free 
water (30 µL) was added directly to the column membrane and the column was 
centrifuged at 10,000 rpm for 1 minute to elute the RNA. The RNA yield of the 
samples was determined with a NanoDrop 1000 Spectrophotometer 
(ThermoScientific) and the samples were stored at -80 oC. 
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2.2.2 RNA and DNA measurements 
 
RNA and DNA concentration measurements were carried out with a 
NanoDrop 1000 Spectrophotometer (Thermoscientific). Purity of DNA and RNA 
samples was assessed using the ratio of absorbance at 260 and 280 nm with a ratio of 
~1.8 for “pure” DNA and ~2.0 for “pure” RNA.  
 
 
2.2.3 cDNA synthesis 
 
Reverse Transcriptase polymerase chain reaction (RT-PCR) was used to 
synthetise complementary DNA (cDNA) from RNA samples. For this purpose, 1-2 
µg of extracted RNA, 1 µL/µg RNA of Random Primers (0.5 µg/µL, Promega) and 
RNase-free water to a volume of 13 µL were mixed in a 0.5 mL Eppendorf tube, 
heated at 70 oC for 5 minutes (Px2 Thermal Cycler, Thermo Electron Corporation) 
and quickly chilled on ice. Following this, 12 µL of mastermix, containing 5 µL of 
M-MLV 5x Reaction buffer (Promega), 1 µL each of dATP, dCTP, dGTP and dTTP 
(10 mM, Bioline), 1 µL M-MLV Reverse Transcriptase (200 U/µL, Promega), 0.625 
µL of RNasin® Plus RNase Inhibitor (40 U/µL, Promega) and RNase-free water to 12 
µL, were added to the mixture and the tube incubated at 37 oC for 60 minutes 
followed by 10 minutes at 95 oC to inactivate the reverse transcriptase. Finally, the 
DNA concentration of the obtained cDNA samples was measured with a NanoDrop 
1000 Spectrophotometer and the samples were stored at -20 oC. 
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2.2.4 PCR amplification 
 
Primers for equine P2X1-7 receptors amplification were designed with the 
primer design software PrimerExpress v3.3 or manually (P2X3), based on the 
predicted equine P2X1-7 mRNA sequences in NCBI (National Centre for 
Biotechnology Information) and Ensembl databases (Table 2.1). 
Primers were designed with at least one primer from a pair spanning an exon 
junction and with the forward and reverse primers located on different exons 
(thereby spanning an intron). The amplicon length was set to 150-1000 base pairs 
and where possible, the amplicon was selected to be closer to the 3’ end of the 
mRNA sequence (nucleotide sequence at the 3’ end generally more fully elucidated). 
The following primer design parameters were also set for a successful amplification. 
Primer length was set to 16-24 base pairs and the primer melting temperature was set 
between 58 and 60 oC (within 2 oC of each other). The primers’ GC content was set 
to 30-60% with not more than 3 Gs or Cs in the last 5 bases at the 3’ end of the 
primer. Furthermore, the number of maximum consecutive complementary primer 
base pairs was set to 4 and the number of maximum total complementary primer base 
pairs was set to 8. Finally, the primer pair candidates were screened for specificity 
against the equine transcriptome (NCBI Transcript Reference Sequences) with the 
online tool Primer-BLAST (NCBI). Table 2.2 summarises equine P2X1-7 primers 
and their properties. 
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Table 2.1. Equine predicted P2X1-7 transcripts accession numbers, NCBI and 
Ensembl databases. 
Accession number P2X receptor 
NCBI Ensembl 
P2X1 XM_001504730.1 ENSECAT00000010642 
P2X2 - ENSECAT00000017460 
P2X3 XM_001504914.1 ENSECAT00000018031 
P2X4 XM_001492153.2 ENSECAT00000025636 
P2X5 XM_001918102.1 ENSECAT00000026624 
ENSECAT00000026645 
P2X6 or 
P2X-like 1 orphan 
receptor 
XM_001488204.2 ENSECAT00000009106 
(ENSECAT00000000120) 
(ENSECAT00000019561) 
P2X7 XM_001495572.1 ENSECAT00000010815 
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   Table 2.2. Equine primers used in PCR reactions. 
Primer pair Sequence Amplicon length Annealing temperature 
eqP2X1 forward TGAGTACGACACGCCTCGAA 569 bp 59oC 
 reverse TGCGCCTTTTGACCTTGAA   
eqP2X2 forward AATTCCAGTTCTCTAAGGGCAACA 186 bp 59oC 
 reverse CCCAGTTGATAATGACCCCAAT   
eqP2X3 forward CAGTGGAAATGCCTGTCATGA 281 bp 59oC 
 reverse GGCCTTGTCCAAGTCGCA   
eqP2X4 forward CGGCTACAACTTCAGGTTTGC 272 bp 59oC 
 reverse CCTGATCGTAATCTGCCACATATT   
eqP2X5 forward ACCCCAGGGAGAGAACGTCTT 527 bp 60oC 
 reverse TGCATTCGGAGGGAGCTTTAT   
eqP2X6 forward CAACTTCAGGACAGCCACTCACT 216 bp 59oC 
 reverse GCTTCTCCATCCACGTACAACA   
eqP2X7 forward TTCCTACGTTATCTTTGCCTTGGT 169 bp 59oC 
 reverse GGTGTAGTCTGCGGTGTCGAA   
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PCR was used to amplify equine P2X1-7 cDNA from cDNA samples. PCR 
reactions were performed in 50 µL final volumes containing 5 µL of 10x PCR Buffer 
(with MgCl2, Sigma-Aldrich), 1 µL of dNTP mix (10 mM, Bioline), 15 pmol each of 
the appropriate forward and reverse primers (Applied Biosystems) (Table 2.2), 0.5 
µL Taq DNA Polymerase (5 U/µL, Sigma) and 1 µL of cDNA sample in distilled 
water. Cycling conditions consisted of a step of denaturation at 94 oC for 10 minutes, 
35 cycles of denaturation at 94 oC for 30 seconds, annealing at primer-specific 
temperature (Table 2.2) for 30 seconds, and elongation at 72 oC for 1 minute, 
followed by a final elongation step at 72 oC for 10 minutes (Px2 Thermal Cycler, 
Thermo Electron Corporation). In all experiments, negative controls were included 
which substituted distilled water for template. 
 
 
2.2.5 PCR products DNA agarose gel electrophoresis 
 
PCR amplified products were analysed by agarose gel electrophoresis. 
Agarose gels were composed of 1% (w/v) agarose (Promega) in 1x TAE buffer (50x 
TAE buffer, Bio-Rad) containing 5 µL per 100 mL ethidium bromide (10 mg/mL, 
Bio-Rad). After the gel had polymerised, it was transferred to a gel electrophoresis 
tank and submerged in 1x TAE buffer. 10 µL of PCR product were mixed with 2 µL 
of GelPilot DNA loading dye 5x (Qiagen) prior to loading into the wells of the gel. 
TrackIt™ 1 Kb Plus DNA ladder (Invitrogen) (10 µL) was used alongside PCR 
products. Electrophoresis was performed at a constant voltage of 140 V for 50-60 
minutes or 80 V for 40-50 minutes, depending on the size of the gel. DNA products 
were visualised under a UV transilluminator (GeneGenius BioImaging System) and a 
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photograph was taken (GeneSnap). Acquired images were processed using Adobe 
Photoshop CS3 extended v10.0 image processing programme. PCR amplified 
products’ identity was confirmed by size comparison with the predicted equine 
sequences and by subsequent DNA sequencing. 
 
 
2.2.6 PCR products clean up and gel extraction 
 
PCR amplified products’ identity was confirmed by size comparison of the 
generated amplicon to the predicted sequences and by subsequent DNA sequencing. 
For that purpose, PCR products to be used in subsequent DNA sequencing reactions 
were purified. 
PCR products generating a single band after agarose gel electrophoresis were 
purified with a QIAquick PCR purification kit (Qiagen) according to the 
manufacturer’s instructions. Briefly, Buffer PB was added to PCR samples (5:1) and 
the mixture was applied to a QIAquick column to bind DNA. The column was 
centrifuged at 13,000 rpm for 30-60 seconds and the flow-through discarded. 750 µL 
of Buffer PE was applied to the column and the centrifugation step was repeated. The 
flow-through was discarded and the column was centrifuged at 13,000 rpm for an 
additional 1 minute. The column was then placed in a clean eppendorf tube and 30 
µL of Buffer EB were added to the column membrane. The column was left to stand 
for 1 minute and then centrifuged at 13,000 rpm for 1 minute to elute DNA. 
PCR products generating multiple bands were purified with a MinElute gel 
extraction kit (Qiagen). Briefly, the right sized band was excised of the agarose gel 
with a scalpel and weighed in an eppendorf tube. Buffer QG was added to the gel 
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slice (3:1) (100 µg ≈ 100 µL) and the tube was incubated at 50 oC for 10 minutes or 
until the gel slice had completely dissolved. 1 gel slice volume of isopropanol was 
added to the epperdorf tube and mixed by inverting the tube. The mixture was 
applied to a MinElute spin column, to bind DNA, and centrifuged at 10,000 rpm for 
1 minute. The flow-through was discarded and 500 µL of Buffer QG was added to 
the column. The centrifugation step was repeated and the flow-through discarded. 
750 µL of Buffer PE was added to the column and the column was left to stand 5 
minutes before repeating the centrifugation. The flow-through was discarded and the 
QIAquick column was centrifuged for an additional 1 minute. The column was then 
placed in a clean eppendorf tube and 10 µL of Buffer EB were added to the column 
membrane. The column was left to stand for 1 minute and then centrifuged at 10,000 
rpm for 1 minute to elute DNA. The concentration of the eluted DNA was measured 
with a NanoDrop 1000 Spectrophotometer and the samples were stored at -20 oC. 
 
 
2.2.7 PCR products sequencing and analysis 
 
PCR product identity was confirmed by band size and subsequent DNA 
sequencing. For this purpose, purified PCR products (1 ng DNA/µL per 100 bp) were 
sent along with the corresponding primer pair for sequencing at Source BioScience 
LifeSciences (Nottingham). The DNA sequencing results, forward and reverse 
nucleotide sequences, were read and analysed with 4Peaks software and Microsoft 
Office Word 2008. Reverse nucleotide sequences were converted to forward 
(Complementor tool, justbio.com) and forward and reverse nucleotide sequences 
were aligned (Aligner tool, justbio.com) to get eqP2X1-7 amplicon sequences. 
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eqP2X1-7 amplicon sequences were then compared with the respective predicted 
sequences by NCBI and Ensembl databases (Aligner tool, justbio.com). Where 
changes in nucleotide sequence were noted (compared to the predicted ones), 
alterations of the reading frame and changes in the resulting amino acid sequence 
were investigated (Translator tool, Aligner tool, justbio.com). 
 
 
2.3 Western blot analysis 
 
2.3.1 Protein extraction 
 
Samples collected for Western blot experiments were snap frozen in liquid 
nitrogen and stored at -80 oC until processed for protein extraction. For this purpose, 
tissue samples were weighed and homogenised (for tissue homogenisation see tissue 
homogenisation step in 2.2.1 RNA extraction). The homogenised tissue was then 
placed in ice cold RIPA buffer (Sigma) supplemented with cOmplete Mini protease 
inhibitor cocktail tablets (1 tablet/10 mL of extraction buffer, Roche) (3 mL 
supplemented RIPA buffer/g of tissue), vortexed and incubated on ice for 30 minutes 
before centrifugation at 10,000 g at 4 oC for 10 minutes. The supernatant was 
collected and centrifuged again until the obtained lysate was clear. 
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2.3.2 Protein concentration measurements 
 
The protein concentration of the samples lysates was measured with the 
Pierce BCA protein assay (Pierce BCA protein assay kit, Thermo Scientific). Briefly, 
9 bovine serum albumin (BSA) diluted standards of known protein concentrations, 
ranging from 2000 µg/mL to 0 µg/mL, and the sample lysates to be measured (1:25 
dilution) were prepared in protease inhibitor cocktail complemented RIPA buffer. 
Working reagent (WR) solution (200 µL/replicate of protein standard and unknown 
sample) was then prepared by mixing 50 parts of BCA Reagent A with 1 part of 
BCA Reagent B. 25 µL of protein standards and unknown protein samples were 
loaded in duplicate into a 96-well plate and 200 µL of WR was added to each well. 
The 96-well plate was mixed thoroughly by hand for 30 seconds and incubated at   
37 oC for 30 minutes. After incubation, the plate was allowed to cool to room 
temperature, and was then placed into a photometric microplate absorbance reader 
(Multiskan FC, Thermo Scientific). A colorimetric quantitative analysis was obtained 
at a wavelength of 570 nm with the SkanIt Software 2.5.1 (Thermo Scientific) 
package and quantitative readings were saved in a Microsoft Office Excel 2008 file. 
The average values of protein standards’ and samples’ replicates readings were 
calculated and the average value of the blank standard was subtracted from all other 
averages. A standard curve was then created using the protein standards corrected 
values against their known protein concentrations (µg/ml) and the equation it yielded 
was used for the calculation of protein concentrations of unknown samples. The 
obtained protein concentrations for unknown samples were then multiplied by 25 to 
account for the initial samples’ dilution. Negative control samples substituting water 
for sample were used. 
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2.3.3 Antibody selection 
 
Antibodies raised against equine P2X1-7 receptor proteins are not 
commercially available. Therefore, antibodies raised against other species P2X 
receptor proteins were selected based on the homology of their immunogen peptide 
amino acid sequence to the respective equine predicted amino acid sequence (Table 
2.3). Additionally, P2X1-7 equine proteins are predicted to share similar post 
translational modifications with the human and rat P2X1-7 proteins 
(http://prosite.expasy.org/). 
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Table 2.3. Details of homology of the selected P2X1-7 receptor antibodies immunogen peptides amino acid sequences to the respective equine 
predicted amino acid sequences. 
P2X 
antibody 
Manufacturer Immunogen peptide Species Location Equine sequence (predicted) Similarity 
P2X1 APR-001 
Alomone, Jerusalem 
DPVATSSTLGLQENMRTS rat 382-399 (C-terminus) DPTTTSSTLG LQENMKTS 15/18 83.33% 
P2X2 ab48864 
Abcam, Cambridge 
YPKFHFSKGNIADRTDGY 
LKRCTFHEASDLYCPIFK 
LGFIVEKAGESFTE 
human  205-254 (extracellular) YPKFQFSKGNIENRKDGYL
KRCTFHEVSDLYCPIFKLGFI
VEQAGENFTE 
43/50  86% 
P2X3 RA10109 
Neuromics, Edina 
VEKQSTDSGAYSIGH rat/mouse 383-397 (C-terminus) EEKQSTDSGAYSIGH 14/15  93.33% 
P2X4 ab82329 
Abcam, Cambridge 
GHSFQDMAVEGGIMGIQVNW
DCNLDRAASLCLPRYSFRRLD
TRDVEHNVSPGYNFRFAKYY
RDLAGNEQRTLIKAYGIRFDII
VFGKAGKFDIIPTMINIGSGLA
LLGMATVLCDIIVLYC 
human 240-360 GHSFQDMAVEGGIMGIQIK
WNCNLDRAASLCLPKYSFR
RLDTRDVDHNVSPGYNFRF
AKYYNDLTGTEHRTLIKAY
GIRFDIIVFGKAGKFDIIPTMI
NIGSGLALLGVATVLCDVIV
LYC 
110/121 90.91% 
P2X4 APR-002 
Alomone, Jerusalem 
KKYKYVEDYEQGLSGEMNQ rat 370-388 (C-terminus) KKYKYVADYDQGLGSESD
Q 
13/19 68.42% 
P2X5 APR-005 
Alomone, Jerusalem 
RENAIVNVKQSQILHPVKT rat 437-455 (C-terminus) LGNGKVNVEQPQNLQTVEA 8/19 42.11% 
P2X6 ab80979 
Abcam, Cambridge 
LYVDREAHFYWRTKYEEAK
APKATANSVWRELALASQAR
LAECLRRSSAPA 
human 350-400 LYVDGEAHFYWSTKYEEAK
APKRTAPAP - incomplete 
22/28 78.57% 
P2X7 APR-008 
Alomone, Jerusalem 
KKGWMDPQSKGIQTGRC mouse  136-152 (extracellular) KKGWMDPQSKGIQTGRC 17/17  100% 
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2.3.4 Western blot 
 
Western blot experiments were carried out to validate the use of the selected 
P2X1-7 antibodies in equine tissue. Sample size was set to 25 µg protein following 
preliminary Western blot analysis experiments with sample serial dilutions. Protein 
samples (25 µg) were mixed with lane marker non-reducing sample buffer (Thermo 
Scientific) and DTT (0.1 M) (Sigma) and denatured in a Unitek HBS-130 heated 
rack at 70 oC for 10 minutes. Samples used in Western blots for P2X2, P2X4, and 
P2X6 proteins did not undergo the denaturation step since P2X2, P2X4, and P2X6 
antibodies showed better results with non-denatured samples. A NuPAGE 4-12% 
Bis-Tris gel cassette (Invitrogen) was inserted into an XCell Surelock Mini-Cell gel 
tank (Invitrogen) and submerged with 1x NuPAGE MES SDS Running Buffer (20x 
NuPAGE MES SDS Running Buffer, Invitrogen). Samples and 10 µL of Novex 
Sharp pre-stained protein standard (Invitrogen) were loaded on the gel and separated 
with a Bio-Rad PowerPac 300 at 200 V for 35 minutes. In the meantime, a Protran 
nitrocellulose membrane (Whatman), 2 filter papers and 6 sponge blotting pads were 
pre-soaked in transfer buffer (50 mL of 20x NuPAGE Transfer Buffer (Invitrogen) 
and 200 mL of methanol in 750 mL of ultrapure water) for 15 minutes. After 
sufficient separation of the samples, the gel was taken out of the cassette and a 
gel/blot sandwich was created by placing the pre-soaked nitrocellulose membrane on 
one side of the gel, one piece of pre-soaked filter paper on top of the nitrocellulose 
membrane, and the second piece of pre-soaked filter paper on the other side of the 
gel. All air bubbles were smoothed out and the gel/blot sandwich was placed in the 
Xcell II blot module (Invitrogen) in between the six pre-soaked sponge blotting pads 
with the nitrocellulose membrane on the side facing the anode. The blot module was 
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placed in the gel tank and transfer buffer was added to it before subjecting it to a 
constant power supply of 30 V for 1 hour 40 minutes. 
After sufficient voltage exposure, the nitrocellulose membrane was removed 
from the gel/blot sandwich and placed into a PBS filled plastic tray and agitated on a 
Stuart Scientific Gyro Rocker SSL3 for 5 minutes. PBS was discarded and 1% 
skimmed dry milk PBS (Western blot blocking solution) was added to the membrane 
and agitated at RT for 1 hour to block non-specific binding. The blocking solution 
was then replaced with primary antibody solution, primary antibody (Table 2.4) in 
5% skimmed dry milk PBS 0.1% Tween (PBST), and incubated at 4 oC overnight 
under gentle agitation. 
After sufficient incubation, the primary antibody solution was removed and 
the membrane was washed 3 times in PBST for 5 minutes before adding the 
secondary antibody solution, 1:1000 goat anti-rabbit HRP-conjugated IgG (Sigma) in 
5% skimmed dry milk PBST. The membrane was incubated with the secondary 
antibody solution at RT for 1 hour under gentle agitation. After incubation, the 
secondary antibody solution was discarded and the membrane washed, 3 times in 
PBST for 5 minutes, before adding 6 mL Oxidising Reagent Plus and Enhanced 
Luminal Reagent Plus (1:1) (Western Lightning-Plus ECL detection kit, 
PerkinElmer) and shaking in hand for 1 minute. Excess solution was drained off the 
nitrocellulose membrane and the membrane was placed in a clear plastic cover and in 
a luminescence cabinet (UVP ChemiDoc-it imaging system). The membrane was 
exposed to UV light for 20 to 30 minutes and images were created using 
VisionWorksLS image acquisition and analysis software package and processed 
using Adobe Photoshop CS3 extended v10.0 image processing programme. Equine 
P2X1-7 proteins molecular weight (MW) was calculated based on the predicted 
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amino acid sequences (NCBI, Ensembl) (MW tool, 
http://web.expasy.org/compute_pi/) and protein identification was based on the MW 
of the detected bands. 
Control experiments were carried out with omission of the primary antibody. 
Additionally, for P2X1 and P2X7 receptor proteins, control experiments with pre-
incubation of the primary antibody with its immunogen peptide were carried out. 
Briefly, P2X1 and P2X7 primary antibodies were pre-incubated with their respective 
immunogen peptides (2 µg peptide/µg antibody) (Alomone, Jerusalem) for 1 hour 
under gentle agitation before adding the primary antibody solution to the membrane 
for overnight incubation. 
 
 
2.3.5 Coomassie stain/Mass spectrometry 
 
To validate antibody specificity, the identity of the western blot bands was 
also checked by mass spectrometry. For this purpose, the samples lysates were 
separated electrophoretically on a NuPAGE 4-12% Bis-Tris gel (see 2.3.4 Western 
blot experiments) and stained with a 0.02% Coomassie Brilliant Blue stain solution. 
To prepare 500 mL of 0.02% w/v Coomassie Brilliant Blue stain solution 100 mg of 
Brilliant Blue R (BBR) (Sigma) was dissolved in 20 mL of ultrapure water and 
mixed to 30 mL of methanol. Once BBR was dissolved, 135 mL of methanol, 45 mL 
of acetic acid, and 270 mL of ultrapure water were added to the solution and mixed. 
Once the gel was run, it was placed in a glass container, submerged in 
Coomassie stain solution and left for 2.5 hours under gentle agitation. The 
Coomassie stain solution was then replaced with a Coomassie destain solution (25 
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mL of acetic acid and 25 mL of methanol in 200 mL of ultrapure water) in order to 
visualise the protein bands. The destain solution was left for 30 minutes (under 
gentle agitation) and replaced with some fresh one until the gel matrix was clear. The 
bands corresponding to the bands seen on P2X Western blots were cut out, placed in 
an eppendorf tube and sent to the University of Manchester Protein Mass 
Spectrometry Core Facility for mass spectrometry analysis. 
 
 
2.4 Histology and immunohistochemistry experiments 
 
2.4.1 Samples preparation 
 
Samples for histology or immunohistochemistry were fixed in 4% neutral 
buffered paraformaldehyde (PFA) for 24 hours and sent to the University of 
Liverpool Pathology department where they were embedded in paraffin, cut in 6 µm 
sections and mounted on polylysine slides. 
 
 
2.4.2 Histology 
 
Sections for histologic analysis were sent to the University of Liverpool 
Pathology department where H&E stain was carried out. H&E sections were 
visualised using Nikon eclipse 80i microscope and pictures were acquired with 
Nikon DS-L2 standalone control unit and analysed using Adobe Photoshop CS3 
extended V10.0 image processing programme. H&E stained tissue samples were 
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assessed and descriptive analysis performed. For palmar digital artery and vein, the 
tunica media layer, containing the smooth muscle cells, was measured and expressed 
as a ratio of overall vessel thickness. 
For hoof sections, changes in hoof histology in chronic laminitic horses were 
described as mild, moderate or severe (Hampson et al. 2012). The criteria used for 
the classification of changes in hoof histology included lengthening of the primary 
epidermal lamellae (PEL), attenuation and tapering of the tips of secondary 
epidermal lamellae (SEL) and the presence of abnormal columns of partially 
keratinised cells on either side of the keratinised axis of the PEL for mild changes, 
marked straightening and elongation of the SEL for moderate changes, and loss of 
lamellar architecture and organised recognisable SEL rows. 
Finally, for C4 and C8 DRG sections, neuronal cell body size, small (<30 
µm), medium (30-60 µm), and large (>60 µm) (adapted from Holford et al. 1994), 
and distribution were defined. 
 
 
2.4.3 Immunohistochemistry 
 
Antibody specificity was validated for P2X1-3, 7 antibodies (based on 
Western Blot results) and these were subsequently used in immunohistochemical 
analysis. 
Sections for immunohistochemistry were deparaffinised and rehydrated in 
two washes of xylene, 100%, and 95% ethanol solution for 10 minutes and in two 
washes of ultrapure water for 5 minutes. Once rehydrated, the slides were submitted 
to antigen retrieval treatment. 
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The appropriate antigen retrieval method for each antigen/antibody was 
determined experimentally. The slides were submitted to two heat-induced antigen 
retrieval methods, citrate buffer and ethylenediaminetetraacetic acid (EDTA) buffer, 
two enzymatic antigen retrieval methods, proteinase and trypsin, or no antigen 
retrieval treatment at all, to find the treatment that gave optimal staining for each 
antibody. 
The heat-induced antigen retrieval treatments consisted of incubation of the 
slides in 10 mM citrate buffer pH6 (sodium citrate trisodium salt dihydrate) or 1 mM 
EDTA buffer ph9 at sub-boiling temperature of ~96 oC for 25 minutes. The slides 
were subsequently left in the buffer until it cooled down to RT and washed twice in 
ultrapure water for 5 minutes for citrate buffer or put straight in ultrapure water for 
two washes of 5 minutes for EDTA buffer. The proteinase antigen retrieval treatment 
consisted of incubation of the slides in PBS at 37 oC for 5 minutes, followed by an 
additional 5 minutes in a 0.05% w/v proteinase solution (bacterial proteinase type 
XXIV, Sigma) at 37 oC and finally of two washes in ice-cold Tris Buffered Saline 
(TBS) (2.42 g of Trizma base and 8 g of sodium chloride in 1 L of ultrapure water) 
for 5 minutes. The trypsin antigen retrieval treatment consisted of incubation of the 
slides with 0.25% w/v trypsin (Gibco) at RT for 10 minutes and two subsequent 
washes in TBS for 5 minutes. 
Assession of the obtained staining to determine the antigen retrieval treatment 
that gave the best results for each antibody was based on the presence of staining, the 
location of the staining, the staining intensity, and the presence of background 
staining. Antibodies for P2X1 and P2X2 receptor protein showed optimal staining 
with the proteinase antigen retrieval treatment, whereas P2X3 receptor protein 
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antibody showed optimal staining with the citrate pH6 buffer and P2X7 receptor 
protein antibody with the EDTA pH9 buffer antigen retrieval treatment. 
Following antigen retrieval treatment, the slides were washed in ultrapure 
water for 5 minutes and incubated in a 3% hydrogen peroxide solution for 10 
minutes to block endogenous peroxidase activity. After the endogenous peroxidase 
block, the slides were washed twice in ultrapure water for 5 minutes and then in TBS 
for an additional 5 minutes. 
Each section was subsequently blocked with 400 µL of 10% normal goat 
serum (Vector Laboratories) in TBS (blocking solution) at 25 oC (Roller-Blot 
Hybridiser HB-3D, Techne) for 1 hour to prevent non-specific antibody binding. The 
blocking solution was replaced with 100 µL primary antibody solution, primary 
antibody in blocking solution (Table 2.4), and the slides were incubated at 25 oC for 
1 hour 10 minutes. After sufficient incubation with the primary antibody, the slides 
were washed in TBS three times for 5 minutes, and 95 µL of Zytochem Plus HRP 
Polymer anti-rabbit (Zytomed Systems) was added to each section at 25 oC for 40 
minutes. The slides were washed in TBS three times for 5 minutes before adding 300 
µL of 3’3-diaminobenzidine (DAB) solution (SigmaFast DAB with metal enhancer, 
Sigma) for 30 seconds or 1 minute for P2X3 antibody. Once staining had developed, 
the slides were immersed in ultrapure water for 5 minutes and counterstained in 
Delafield’s hematoxylin (Fluka) for 10 seconds before being washed in tap water. 
Finally, the sections were dehydrated in two washes of 95% ethanol solution, 100% 
ethanol, and xylene for 10 seconds in the first wash and 5 minutes in the second. 
Once dehydrated, the slides were coverslipped with Clarion mounting medium 
(Santa Cruz Biotechnology). 
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The sections were visualised under a Nikon eclipse 80i microscope. Pictures 
were taken with a Nikon DS-L2 standalone control unit and processed with Adobe 
Photoshop CS3 extended V10.0 image processing programme. 
Control experiments were carried out with omission of the primary antibody 
and substitution of the primary antibody with non-immune rabbit polyclonal IgG 
(isotope control) (Abcam). 
 
 
Table 2.4. P2X1-7 antibodies used in Western blot and immunohistochemistry 
experiments with their respective concentrations. Antibody specificity was validated 
for P2X1-3, 7 antibodies and these were subsequently used in immunohistochemical 
analysis. 
Antibody Manufacturer WB antibody 
concentration 
IHC antibody 
concentration 
P2X1 APR-001 
Alomone, Jerusalem 
1:200 1:200 
P2X2 ab48864 
Abcam, Cambridge 
0.6 µg/mL 1:125 
P2X3 RA10109 
Neuromics, Edina 
1:1000 1:1000 
P2X4 ab82329 
Abcam, Cambridge 
1:300 - 
 APR-002 
Alomone, Jerusalem 
1:200 - 
P2X5 APR-005 
Alomone, Jerusalem 
1:200 - 
P2X6 ab80979 
Abcam, Cambridge 
10 µg/mL - 
P2X7 APR-008 
Alomone, Jerusalem 
1:200 1:200 
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2.4.4 Semi-quantitative immunohistochemistry 
 
Semi-quantitative immunohistochemistry was carried out for immunostained 
sections of normal horses and horses suffering from chronic laminitis for P2X 
receptor subtypes and tissues that presented with a special interest (eg. P2X3 receptor 
subunit in DRG). 
Acquired pictures of immunostained sections were analysed for staining 
intensity using Adobe Photoshop CS3 extended V10.0 image processing programme. 
Pictures of all representative fields of the immunostained sections were taken and 
three or five of them were randomly selected for analysis for P2X7 and P2X3 
staining, respectively. The selected pictures were corrected for white balance on 
Adobe Photoshop before proceeding to staining intensity measurements. 
 
P2X3 receptor subtype staining intensity measurements 
For quantification of P2X3 receptor subtype staining intensity in C4 and C8 
DRG neurons, staining intensity was measured in individual cells. Each cell was 
selected and the cell area and mean gray scale intensity for the cell (with exclusion of 
the nucleus) were obtained. All measurements were exported in a text file and 
analysed in Microsoft Office Excel 2008. The diameter of the cells was calculated 
based on the measured cell area (d = 2√(A/π)), and the calculated pixels were 
converted to µm using the scale bar (104 pixels = 100 µm). The cell measurements 
(diameter and gray scale measurements) were sorted in cell diameter ascending order 
for each picture and the cells were split into three categories based on diameter; 
small-sized with d<30 µm, medium-sized with d 30-60 µm, and large-sized with 
d>60 µm. Subsequently, the average and standard deviation of the gray scale 
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measurements were calculated for each cell category in each horse (5 fields) and 
staining intensity in C8 DRG for each horse was normalised against C4 DRG 
staining of the same horse. Finally, normalised C8 DRG staining intensity for 
chronic laminitic horses was expressed as a ratio to normalised staining intensity of 
C8 DRG in non-laminitic horses and plotted against the duration of chronic laminitis. 
For this purpose, 3 variables surface plots were carried out in SigmaPlot for 
Windows 12.5. 
 
P2X7 receptor subtype staining intensity measurements 
For quantification of P2X7 receptor staining intensity in C4 and C8 DRG 
sections, staining intensity was measured by selecting an immunostained structure 
(immunostained myelin sheath) and then expanding the selection to all 
immunostained structures on the picture (Select similar command). The mean gray 
scale intensity of the selection was then recorded and the same process was repeated 
selecting a counterstained nuclei to measure counterstain intensity. All measurements 
were input in an Excel file and the average values were calculated for each horse. 
Finally, P2X7 staining intensity was normalised for respective counterstain intensity 
and corrected values for normal and chronic laminitic horses were tested for 
significance (see 2.8 Statistical analysis). 
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2.5 Electrophysiology experiments 
 
2.5.1 Tissue digestion and neurons extraction 
 
C4 and C8 DRGs were dissected out of normal and chronic laminitic horses 
within 1-2 hours of death, placed in ice-cold growth medium (Dulbecco’s modified 
Eagle’s medium, low glucose, pyruvate (DMEM), 31885-023, Gibco) supplemented 
with 10% foetal calf serum (FCS) (Lonza), 100 U/mL penicillin, 100 mg/mL 
streptomycin (P/S) (Gibco) and 500 ng/mL amphotericin B (F) (Gibco), and 
enzymatically digested for the extraction of DRG neurons. 
The following steps for the extraction of DRG cells were executed in a class I 
laminar flow hood under aseptic conditions with the use of sterile tools and sterile 
filtered solutions (0.2 µm filters, Whatman). The dissected DRGs were washed twice 
in Hank’s balanced salt solution (HBSS) (Gibco), placed in a petri dish in ice-cold 
growth medium, and diced with a scalpel. The diced DRGs were added to the 
digestion solution, 2 mg/mL of collagenase I (Worthington) and 5 mg/mL of dispase 
II (Sigma) in growth medium, and the mixture was incubated in a shaking incubator 
(SI500, Stuart) at 37 oC at 180-200 rpm for 5 hours or overnight until the samples 
were fully digested. 
Once digested, the samples were strained with 40 µm Falcon cell strainers 
(BD) to remove gross tissue debris, centrifuged at 400 g for 5 minutes to spin the 
cells down, and resuspended in HBSS in order to wash the cells. The cells were 
washed a second time in HBSS and a fire-polished Pasteur pipette (Volac, Poulten & 
Graf) was used to triturate the cell suspension and dissociate cell clumps. The cell 
suspension was subsequently gently overlaid onto a 22% isotonic Percoll solution 
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(Sigma) and centrifuged at 950 g for 20 min to remove myelin and cell debris. The 
supernatant containing the myelin and cell debris was discarded and the cells were 
washed twice in HBSS, resuspended in growth medium, plated in 75 cm2 flasks and 
placed in a humidified incubator at 37 oC with an atmosphere of 5% CO2 until use 
the next day. 
 
 
2.5.2 Cell preparation 
 
Whole-cell and perforated whole-cell patch-clamping experiments were 
performed on freshly isolated C4 and C8 DRG neurons for 1 to 4 days after 
extraction. 
For this purpose, plated cells were lifted from the 75 cm2 flasks using trypsin. 
Briefly, growth medium was removed and the cell layer was washed twice with 
HBSS, before 2.5 mL of 0.25% Trypsin-EDTA (Gibco) was added to the cells. The 
cells were incubated at 37 oC for 5 minutes and and a volume of growth medium 
equal to the volume of trypsin was used to halt digestion. The cells were then 
transferred to a 15 mL falcon tube, spun down, and washed twice in HBSS, before 
resuspending in serum free growth medium (supplemented DMEM without FCS) 
and plating at high density (empirical) on poly-L-lysine coated glass-bottom Petri 
dishes (35 mm with 14 mm hole). Plated Petri dishes were left for a minimum of 30 
minutes in a humidified incubator (37 oC, 5% CO2) for neurons to adhere. 
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2.5.3 Set up 
 
Microscope 
For patch-clamping, an inverted compound microscope with fixed stage set 
up on an anti-vibration table was used. An electrode holder was positioned on a 
manual micromanipulator and connected to a remote hydraulic micromanipulator for 
the fine movement of the electrode. The electrode was connected to an Axopatch 
200a amplifier (Axon Instruments, USA) and a DigiData 1200B interface (Axon 
Instruments, USA) attached to a PC running the WinEDR software (Dr. John 
Dempster, University of Strathclyde) for data acquisition. Finally, a ground 
electrode, connected to the amplifier’s circuit ground terminal, was placed in the dish 
water bath to set the zero level. 
 
Water bath and agonist and antagonist delivery 
A constant perfusion system was set up with one tip providing fresh 
extracellular solution (Table 2.5) and the other one draining the overflowing solution 
in a waste container. P2X agonists were applied locally onto the patched neuron with 
a U-tube drug delivery system and P2X antagonists were perfused into the bath (for 
10 min) before agonist application. 
 
Micropipettes 
Patch micropipettes were pulled from fire-polished 1.5mm o.d. borosilicate 
capillary tubes (Sutter Instrument, Novato CA, USA, supplied by INTRACEL, UK) 
with a vertical two-step electrode puller (PC-10 Puller, Narishige). When filled, the 
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fabricated micropipettes had a resistance in the range of 5-9 MΩ for whole-cell 
patch-clamping and 1.6-4 MΩ for perforated whole-cell patch-clamping. 
 
Cell selection 
Neurons were identified amongst other DRG cells based on their size (larger 
than all other DRG cells). A suitable neuron for patch-clamping was selected, and 
moved to the centre of the microscope field. Suitable cells included single, phase-
bright cells isolated from neighbouring cells and potential debris (Figure 2.4a). 
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Figure 2.3 Schematic of the patch clamp technique. A glass micropipette is pressed 
against a cell to form a high resistance electrical seal and the electrode contained in 
the micropipette converts ion currents generated by the cell into electrical currents 
which are read by the amplifier (patch clamp). 
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2.5.4 Whole-cell patch-clamp 
 
The bottom half of a glass micropipette was filled with internal pipette 
solution (filtered, 0.2 µm filter) (Table 2.5) and trapped air bubbles were removed by 
gentle tapping of the pipette shaft. The micropipette was then attached to the 
electrode holder and its tip was dipped into the bath. The Seal test was selected in the 
WinEDR software and the Seal test protocol was run. The micropipette was 
manoeuvred near the centre of view and gradually brought down over the cell. The 
fine controls of the manipulator were then used to bring the pipette down onto the 
surface of the cell. Once contact was made with the cell, the electrode resistance, 
monitored on the computer screen, spontaneously increased. At this stage, gentle 
suction was applied to the micropipette to help the formation of a seal. As the seal 
started forming, the micropipette resistance gradually increased and the trace on the 
computer screen took the shape of a flat line. 
Once a stable seal of a resistance higher than 1 GΩ (gigaseal) was achieved, 
attempts were made to break the cell membrane patch under the pipette to achieve a 
whole-cell patch-clamp. Rupture of the cell membrane and electrical access to the 
intracellular space was indicated on the computer screen by the sudden appearance of 
large capacity transients at the leading and trailing edges of the pulse. If a gigaseal or 
a whole-cell configuration could not be achieved the cell was dropped, the 
micropipette discarded, and a new cell was located to repeat the procedure. 
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Table 2.5. Composition of electrophysiology extracellular and intracellular solutions. 
Extracellular solution  Intracellular solution 
NaCl 150 mM 8.77 g/L  C6H11KO7 140 mM 32.80 g/L 
MgCl2 1 mM 0.20 g/L  NaCl 5 mM 0.29 g/L 
CaCl2 1 mM 0.11 g/L  EGTA 10 mM 3.80 g/L 
D-glucose 10 mM 1.80 g/L  HEPES  10 mM 2.38 g/L 
HEPES mM 10 mM 2.38 g/L     
pH adjusted at 7.4  pH adjusted at 7.3 
 
 
2.5.5 Perforated whole-cell patch-clamp 
 
For the perforated whole-cell patch-clamp technique, an amphotericin B 
solution (210 µg/mL) was used for the internal pipette solution. The amphotericin B 
stock solution was made up in dry dimethylsulfoxide (DMSO) (30 µg/µL) and kept 
away from light at -20 oC (for up to one week). The amphotericing B working 
solution was prepared by mixing 7 µL of stock solution in 993 µL of pipette solution. 
During the experiments, the working solution was kept on ice in the dark and 
renewed every 2-3 hours. The bottom half of the micropipette was filled with the 
amphotericin B solution and the micropipette’s tip was backfilled with the internal 
pipette solution by dipping the tip in the internal pipette solution for 3 to 5 seconds. 
A neuron to clamp was then selected and a stable gigaseal was formed following the 
same procedure as for the whole-cell patch-clamp technique. Once a gigaseal was 
formed, the amphotericin B solution contained in the micropipette was left to work 
until access to the intracellular space was gained or for a maximum of 40 minutes. 
Perforation of the cellular membrane was identified on the computer screen by the 
appearance of large capacity transients at the leading and trailing edges of the pulse. 
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If no change was observed after 40 minutes, the cell was dropped, and a new pipette 
with fresh amphotericin B solution was used on a new cell. 
 
 
2.5.6 Patch-clamp recordings 
 
Recordings were made with the cells held at -60 mV and data were acquired 
with a DigiData 1200B interface (Axon Instruments, USA) attached to a PC running 
the WinEDR software (Dr. John Dempster, University of Strathclyde). 
 
 
2.6 Intracellular calcium measurements 
 
2.6.1 Cells 
 
Calcium measuring experiments were carried out in C8 DRG cells cultured to 
confluence and freshly isolated C8 spinal cord segment cells. For this purpose, C4 
and C8 DRGs and spinal cord segments were dissected out of normal horses, placed 
in ice-cold medium (P/S, F, and 10% FCS DMEM) and processed for cell extraction 
(see 2.5.1 Tissue digestion and neurons extraction). The extracted cells were used 
directly (spinal cord) or plated in 75 cm2 flasks and cultured to confluence (C8 
DRG). After culture, the DRG cell population was mainly consisting of supportive 
cells, ie. satellite glial cells, Schwann cells, and fibroblasts, and few or no neurons 
(Figure 2.4b). 
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The viability of the extracted or cultured cells was determined with the trypan 
blue exclusion method. Briefly, 10 µL of 0.4% trypan blue solution (Sigma Aldrich) 
was mixed with 40 µL of cell suspension (1:5) and left at room temperature for 2-3 
minutes. The cell suspension (20 µL) was then pipetted into a haemocytometer 
chamber and the live and dead cells contained in 5 squares were counted under the 
microscope. The calculated percentage of unstained cells (vs total number of cells) 
represented the percentage of viable cells. 
Furthermore, in order to be used in calcium measuring experiments, the cell 
density of the cell suspensions was determined. For this purpose, approximately 20 
µL of cell suspension was pipetted into a haemocytometer chamber and the number 
of cells in 5 squares was counted under the microscope. The average count of cells 
per square was then calculated and the total number of cells per mL was calculated 
(cells per mL = average count of cells per square x 104). 
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Figure 2.4. (a) DRG neuron for patch-clamping (circled); single, phase-bright, and 
isolated from neighbouring cells and potential debris. (b) DRG cells after culture. 
The population is mainly consisting of supportive cells and few neurons (asterisk). 
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2.6.2 Dye, cell preparation, and equipment 
 
For calcium measuring experiments, Fura-2 AM (Ca2+) indicator (Life 
Technologies) was used, a UV excitable ratiometric fluorescent dye with excitation 
peaks of 340 nm (Ca2+-bound dye) and 380 nm (Ca2+-free dye) and an emission peak 
of 510 nm (Paredes et al. 2008). 
In order to load Fura-2 AM into the cells, the plated cells were trypsinised 
(see 2.5.2 Cell preparation) and resuspended in phenol red-free DMEM (11880-028, 
Gibco) (supplemented with L-glutamine, Gibco) or bicarbonate-free MOPS-buffered 
isotonic saline (Table 2.6). The cell suspension was then incubated with 6 µM of 
Fura-2 AM at 37 oC for 30 minutes in the dark. After incubation, the cells were 
washed twice and resuspended in phenol red-free DMEM or bicarbonate-free 
MOPS-buffered isotonic saline at a density of 250,000 cells/mL or 500,000 cells/mL, 
for fluorescence plate reader or spectrofluorimeter recordings, respectively. 
Recordings were made in a fluorescence plate reader (FLX800 Microplate 
Fluorescence Reader, Bio-Tek Instruments Inc) or a spectrofluorimeter (F-2000 
Fluorescence spectrophotometer, Hitachi), both regulated at 37 oC. The dye was 
alternately excited at 380 nm and 340 nm, with fluorescence emission measured at 
510 nm. 
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Table 2.6. Bicarbonate-free MOPS-buffered isotonic saline composition. 
Bicarbonate-free MOPS-buffered isotonic saline 
NaCl 145 mM 8.47 g/L 
KCl 5 mM 0.37 g/L 
MgSO46H2O 1 mM 0.20 g/L 
CaCl2 2 mM 2 mL of 1 M solution (110.99 
g/L) 
MOPS 10 mM 2.09 g/L 
D-glucose 10 mM 1.80 g/L 
pH adjusted at 7.4 at 37 oC 
 
 
2.6.3 Fluorescence plate reader recordings 
 
Recordings in the fluorescence plate reader were carried out in C8 DRG cells 
from one normal horse (cultured to confluence). For this purpose, 200 µL of Fura-
loaded cell suspension (250,000 cells/mL) was loaded in the wells of a black 96 well-
plate and the potent P2X7 agonist, 2′(3′)-O-(4-benzoylbenzoyl)adenosine 5′-
triphosphate triethylammonium salt (BzATP) (Sigma), and the non-selective P2X 
antagonist, iso-pyridoxalphosphate-6-azophenyl-2',5'--disulfonic acid tetrasodium 
salt (iso-PPADS) (Tocris Bioscience), were used to challenge the cells. BzATP was 
used at concentrations of 10, 50, 100, 500 µM and 1 mM and iso-PPADS was used at 
a concentration of 20 µM (Table 2.7). 
Fluorescence was, initially, measured in resting cells to establish a signal 
baseline and then in agonist and antagonist challenged cells to record changes in 
intracellular calcium ([Ca2+]i) levels. For this purpose, single F340 and F380 
fluorescence measurements were taken from the wells before and straight after the 
addition of BzATP (10, 50, 100, 500 µM and 1 mM) (n = 1). Subsequently, 20 µM 
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iso-PPADS was added to fresh cells, the plate was incubated at 37 oC for 30 minutes 
in the dark, and single F340 and F380 fluorescence measurements were taken from the 
iso-PPADS-incubated cells before and straight after the addition of BzATP (10, 50, 
100, 500 µM and 1 mM) (n = 1). 
 
 
2.6.4 Spectrofluorimeter recordings 
 
Calcium measuring experiments with the spectrofluorimeter were carried out 
in C8 DRG cells from two normal horses cultured to confluence and freshly isolated 
C8 spinal cord cells from one normal horse. For this purpose, 750 µL of cell 
suspension (500,000 cells/mL) was placed in a polystyrene semi-micro cuvette 
(Sarstedt) for each series of measurements while the stock of loaded cells was 
maintained on ice in the dark. 
Background measurements were performed to correct for buffer fluorescence 
and cell autofluorescence. For this purpose, 5 F340 and F380 fluorescence 
measurements were made in the used cell suspensions in absence of Fura-2AM dye 
and these were used to correct subsequent F340 and F380 measurements. 
Selective and non-selective P2X agonists and antagonists were used to 
challenge the cells and the cells’ intracellular calcium responses were recorded. 
Specifically, the non-selective P2X agonist ATP (Sigma) was used at concentrations 
of 5, 10, 50, 100, 200 and 500 µM (C8 spinal cord cells, n = 1), the potent P2X7 
agonist BzATP was used at concentrations of 0.5 , 5 and 50 µM in preliminary 
experiments (C8 DRG cells, n = 1) and 10, 50, 100, 200 µM (C8 DRG cells, n = 3), 
the non-selective P2X antagonist iso-PPADS at a concentration of 20 µM (C8 DRG 
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cells, n = 3), and the P2X7 selective antagonist BBG (BDH) at a concentration of 1 
mM (C8 DRG cells, n = 3). The use of P2X antagonists was combined with 
stimulation of the cells with 100 µM BzATP. 
For stimulation experiments, 5 fluorescence measurements were initially 
made to establish the signal baseline in resting cells (before the addition of the 
agonist). The agonist was then added to the cell suspension and signal recordings 
were made for periods of 300 seconds, with intervals of 2-3 seconds for the first 30 
seconds (0-30 seconds), 10 seconds for the next 150 seconds (30-180 seconds), and 
30 seconds for the last 120 seconds (180-300 seconds). For P2X antagonists, the cell 
suspension was preincubated with the antagonist for 10 minutes at 37 oC in the dark 
before being placed in the spectrofluorimeter. Once in the spectrofluorimeter, 
fluorescence measurements were made as mentioned above. Measurements were also 
carried out in calcium free buffer, bicarbonate-free MOPS-buffered isotonic saline 
lacking CaCl2 and supplemented with ethylene glycol tetraacetic acid (EGTA) (1 
mM) (Sigma) to chelate Ca2+, after stimulation with 5 µM of BzATP (C8 DRG cells, 
n = 1). Measuresements were carried out as mentioned above for 120 seconds. 
 
 
2.6.5 Data analysis 
 
Data were acquired and transferred to an Excel spreadsheet for analysis. 
Average values for background measurements at each wavelength were calculated 
and subtracted from respective subsequent measurements to correct for background 
and autofluorescence. F340/F380 (FCa-bound/FCa-free) fluorescence ratios, reflecting 
[Ca2+]i concentrations, were then calculated for all measurements using the corrected 
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values. For the signal baseline in resting cells where multiple measurements were 
taken, the average value of these measurements was calculated and used. F340/F380 
fluorescence ratios following agonist addition were expressed in graphs in relation to 
baseline signal by subtracting baseline F340/F380. Also, maximum fold or percent 
changes in Fura-2 fluorescence were calculated for all used P2X agonists and 
antagonists by dividing the maximal F340/F380 by the baseline F340/F380. For P2X 
antagonists, the percent of inhibition was also calculated. For this purpose, the 
difference in maximal F340/F380 with and without the antagonist was divided by the 
maximal F340/F380 without the antagonist. Finally, where replicates were used the 
mean was calculated and expressed as mean ± stardard deviation (SD). 
 
 
2.7 Intracellular calcium imaging 
 
For calcium imaging experiments, Fluo-4 AM (Ca2+) indicator (Life 
Technologies) was used; a single wavelength dye with an excitation peak of 494 nm 
and an emission peak of 506 nm. Fluorescence was monitored with a Olympus CK40 
microscope (equipped with a CX-DMG-2 mirror cube) and recorded with ProgRes® 
Mac CapturePro 2.7 software (Jenoptik). 
Cells used in calcium imaging experiments were freshly isolated from C8 
DRG from three normal horses (see 2.5.1 Tissue digestion and neurons extraction). 
Extracted DRG cells were resuspended in phenol red-free DMEM at low density 
(empirical) and plated in poly-L-lysine coated 24-well plates (0.01% poly-L-lysine 
solution, Sigma). The cells were left to adhere overnight in a humidified incubator 
(37 oC, 5% CO2). Once the cells were attached to the wells, the growth medium was 
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discarded and the cell layer was washed with sterile PBS before loading the Fluo-4 
AM dye. For this purpose, the cells were incubated with 5-10 µM of Fluo-4 AM at 
37 oC for 30 minutes in the dark. One well was loaded with dye at each time so the 
used cells were always freshly loaded. After incubation, the cells were washed twice 
and phenol red-free DMEM was added to the well. The cells were left for 10 
additional minutes in the dark in a humidified incubator  before use. 
The 24-well plate was placed under the microscope and neuron cells were 
identified based on size. A photo of the cells in a resting state was acquired with 
ProgRes® Mac CapturePro 2.7 software before addition of the agonist. After addition 
of the agonist, photos of the stimulated cells were taken every 2 seconds for 60 
seconds. The agonist used in this experiment was ATP at a concentration of 1 mM. 
The photos acquired with ProgRes® Mac CapturePro 2.7 software were 
analysed with Adobe Photoshop CS3 to measure fluorescence intensity. The 
fluorescence intensity of the background was measured using mean gray value 
measurements to correct cell fluorescence for background fluorescence. The cell of 
interest was then selected and the mean gray value of the cell was obtained. The 
process was repeated for all photos with the same selection and the acquired values 
were input in an Excel sheet. Background fluorescence intensity values were 
subtracted from the respective cell fluorescence intensity values to correct for 
background fluorescence and the changes to fluorescence 30 seconds after agonist 
application were calculated by dividing the fluorescence at 30 seconds after agonist 
application by the baseline fluorescence in resting cells (F/Frest). 
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       Table 2.7. Summary of cells, materials and P2X agonists and antagonists used in intracellular calcium measuring and imaging experiments. 
 Calcium measuring experiments Calcium imaging experiments 
 Fluorescence plate reader Spectrofluorimeter  
Tissue C8 DRG C8 DRG and spinal cord C8 DRG 
Dye Fura-2 AM Fura-2 AM Fluo-4 AM 
Cell 
preparation 
cell suspension 250,000 cells/mL cell suspension 500,000 cells/mL plated in 24-well plates (low density) 
    
Equipment fluorescence plate reader (FLX800 
Microplate Fluorescence Reader, 
Bio-Tek Instruments Inc) 
spectrofluorimeter (F-2000 
Fluorescence spectrophotometer, 
Hitachi) 
Olympus CK40 microscope, CX-
DMG-2 mirror cube 
P2X agonists BzATP (10, 50, 100, 500, 1000 µM) ATP (5, 10, 50, 100, 200, 500 µM) 
BzATP (10, 50, 100, 200 µM) 
ATP (1 mM) 
P2X 
antagonists 
iso-PPADS (20 µM) iso-PPADS (20 µM) 
BBG (1 mM) 
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2.8 Statistical analysis 
 
Data were tested for Normality using the Shapiro-Wilk test (SPSS Statistics 
21 and web version http://sdittami.altervista.org/shapirotest/ShapiroTest.html) 
significant differences in data sets were determined with Student’s t test 
(independent, two tailed) (Microsoft Office Excel 2008). The level of significance 
was set at P < 0.05 and data were presented as mean ± SD. For correlation analysis 
of hoof changes vs. time, the Pearson correlation coefficient (r) was calculated. 
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Chapter 3 
 
Distribution of purinergic P2X receptors in the 
equine digit, cervical spinal cord and dorsal root 
ganglia 
 
(published work under the title «Distribution of purinergic P2X receptors in the 
equine digit, cervical spinal cord and dorsal root ganglia» Zamboulis et al. (2013) 
Purinergic Signalling PMID: 23381684) (see Appendix for full text) 
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3.1 Introduction 
 
The recognition of ATP as an extracellular signalling molecule was noted in 
the 1920s (Drury & Szent-Györgyi 1929), but it was the late 1970s when ATP was 
reported to induce pain sensation (Burnstock 2006). Since this time, ATP activation 
of purinergic signalling pathways has been described in neurons and related cells in 
both the peripheral and central nervous systems (North 2004, Abbracchio et al. 
2009). In addition to functions in the nervous tissues, the role of P2X receptor 
activation by ATP in non-excitable cells (such as leukocytes and epithelial cells) is 
being increasingly recognised (Burnstock & Verkhratsky 2010). Endogenous ATP 
release by endothelial and epithelial cells in response to alterations in the local tissue 
environment (for example, hypoxia/acidosis) can result in responses such as cell 
proliferation, differentiation and survival (Ray et al. 2002, Schwiebert et al. 2002). 
Differences in P2X receptor subtype expression within and between tissue types may 
therefore allow for tissue- and zonal-specific response to extracellular ATP release 
and help to elucidate the potential role of P2X receptors in a number of physiological 
and pathological processes. 
Purinergic signalling in the horse has received little attention. Ko et al. (1994) 
first investigated purinergic signalling in horses in cultured sweat gland epithelial 
cells with the existence of P2Y receptors in equine sweat gland later confirmed 
(Wilson et al. 1998, Bovell et al. 2013). Also, Zerpa et al. (2013) report the presence 
of P2X1-3 and 7 receptor subtypes in equine digital vessels and their implication in 
regulation of vascular tone. Evidence for the presence of purinergic signalling in the 
horse therefore exists. P2X receptor subtype distribution in equine tissues, however, 
has not been extensively studied and is of interest for its participation in the 
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regulation of physiological processes in the horse. 
The aim of this chapter was to identify and characterise the distribution of 
P2X receptor subtypes in tissues in the equine digit and associated nervous tissue, 
including the peripheral nerves, dorsal root ganglia and cervical spinal cord with a 
view to understanding their role in these tissues. For this purpose, primers for equine 
P2X1-7 receptor transcripts were designed and the existence of P2X1-7 mRNA 
expression in these tissues was investigated. Subsequently, Western blot experiments 
were run to validate the specificity of the selected P2X receptor antibodies in equine 
tissue and investigate P2X receptor subtype protein expression. Finally, 
immunohistochemistry experiments were carried out to determine the cellular 
distribution of P2X1-3, 7 receptor subtypes in sampled tissues. 
 
 
3.2 Study design 
 
• Sample collection – Tissue samples were collected from euthanased horses  
(n = 5) with no previous history or evidence of forelimb or neurological 
diesease. Sampled tissues included the palmar digital artery, vein, and nerve, 
hoof, ipsilateral C8 DRG and spinal cord (innervating the hoof) and 
ipsilateral C4 DRG and spinal cord (not innervating the hoof) (see 2.1 
Samples p.35). 
 
• Identification of P2X1-7 receptor subtype mRNA signal in equine tissue 
– mRNA was extracted from sampled tissues and reverse transcription was 
carried out to synthesize cDNA. Primers for equine P2X1-7 mRNA were 
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designed (based on predicted sequences from NCBI and Ensembl databases) 
and used in PCR reactions for amplification of P2X1-7 cDNA. PCR products 
identity was confirmed by size comparison with the predicted equine 
sequences and by subsequent DNA sequencing (see 2.2 Molecular biology 
experiments p.39). 
 
• Validation of P2X1-7 antibodies in equine tissue – Proteins were extracted 
from sampled tissues and used in western blot analyses carried out to validate 
P2X1-7 antibodies in equine tissue. Western blot bands’ identity was 
confirmed by size comparison with (the MW of) predicted amino acids 
sequences, preincubation of the antibodies with their respective immunogen 
peptides, and mass spectrometry analysis (see 2.3 Western blot analysis 
p.48). 
 
• Characterisation of P2X1-3, 7 receptor subtype proteins distribution in 
equine tissue – P2X1-3. 7 antibodies validated in equine tissue were used for 
immunohistochemical characterisation of their respective proteins’ 
distribution in equine sampled tissues. P2X1-3, 7 antibodies staining 
specificity was confirmed with immunohistochemistry control experiments 
with omission of the primary antibody and with substitution of the primary 
antibody with non-immune rabbit IgG (see 2.4.3 Immunohistochemistry 
p.56). 
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3.3 Results 
 
3.3.1 Molecular biology experiments 
 
All designed primers produced PCR products of the expected size and    
P2X1-7 transcripts were expressed in all sampled equine tissues (Figure 3.1). 
The identification of P2X1-7 amplified products as P2X1-7 amplicons was 
based on their size and subsequent DNA sequencing and genome-wide similarity 
searches (Blast, NCBI). Comparison of the produced nucleotide sequences with the 
predicted ones gave a perfect match for all but the P2X5 transcript which was found 
to combine parts of sequences matching the NCBI predicted P2X5 transcript 
(XM_001918102.1), the Ensembl predicted P2X5 transcripts 
(ENSECAT00000026624, ENSECAT00000026645) or neither NCBI/Ensembl 
predicted P2X5 transcripts (Table 3.1 and 3.2). The mismatches in P2X5 nucleotide 
sequence did not result in interruption or overall alteration of the transcript’s reading 
frame but the resulting amino acid sequence was altered for the codons containing 
the mismatches (Table 3.3). P2X1-7 amplicons from all tissues were sequenced and 
tissue-related differences in the nucleotide sequences were not detected. 
P2X1, 3-6 receptor subtype partial coding sequences (cds) were deposited in 
NCBI database (accession KC790392 to KC790396, respectively). 
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Figure 3.1. Representative bands from agarose gel electrophoresis of eqP2X1-7 PCR 
products from sampled equine tissues cDNA (P2X1- P2X4 and P2X7 C8 DRG, 
P2X5 and P2X6 C4 DRG) showing products of the expected size. bp = base pairs 
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Table 3.1. Nucleotide sequences of sequenced equine P2X1-4, 6 & 7 PCR products. Highlighted in grey are the nucleotide sequences for the 
forward and reverse primers. 
P2X amplicon Nucleotide sequence 
P2X1 amplicon TGAGTACGAC ACGCCTCGAA TGGTGCTGGT TCGCAACAAG AAGGTGGGCG TCGTCTTCCG CCTGATCCAG CTCGTGGTTC TGGTCTACGT CATTGGGTGG 
GTGTTTGTCT ACGAGAAGGG TTACCAGACC TCCAGCAGCC TCATCAGCAG CGTGTCTGTG AAACTCAAGG GCCTGGCAGT GACGCAGCTC CCAGGCCTGG 
GCCCCCAGGT CTGGGACGTG GCTGACTACG TCTTCCCAGC TCAGGGCGAC AACTCCTTTG TGGTCATGAC CAATTTCATC GCGACCCCAA AGCAGGCTCA 
AGGCTACTGT GCAGAGCACC CGGAAGGCGG CACGTGCGCG GATGATAGCG GCTGCATCCC TGGGAAGGCA GAGAGGAAGG CCCAAGGCAT CCGCACGGGC 
AAGTGTGTGG CCTTCAATGA CACCGTGCAA ACGTGTGAGA TCTTTGGCTG GTGCCCCGTG GAGGTGGACG ATGACATCCC ACGCCCTGCC CTTCTCCGAG 
AGGCCGAGAA CTTCACTCTC TTCATCAAGA ACAGCATCAG CTTTCCACGC TTCAAGGTCA AAAGGCGCA 
P2X2 amplicon AATTCCAGTT CTCTAAGGGC AACATTGAGA ACCGGAAGGA TGGCTACCTG AAACGCTGCA CATTCCATGA GGTCTCGGAT CTCTACTGCC CCATTTTCAA 
GCTGGGCTTC ATAGTGGAGC AGGCAGGGGA AAACTTCACG GAGCTGGCAC ACACGGGTGG CGTCATTGGG GTCATTATCA ACTGGG 
P2X3 amplicon CAGTGGAAAT GCCTGTCATG ATGGAAGCTG AGAATTTCAC TATTTTCATC AAGAACAGCA TCCGTTTCCC TCTCTTCAAC TTTGAAAAGG GTAACCTGCT 
TCCCAACCTG ACGGCCGCCG ACATAAAGAC ATGCCGCTTC CACCCTGACA AGTCCCCTTT CTGCCCCATC TTGCGGGTGG GGGATGTGGT CAAGTTTGCG 
GGGCAGGATT TTGCCAAACT GGCCAGCACG GGTGGAGTTC TGGGCATTAA GATTGGCTGG GTGTGCGACT TGGACAAGGC C 
P2X4 amplicon CGGCTACAAC TTCAGGTTTG CCAAGTACTA CAATGACCTG ACAGGCACAG AGCACCGCAC ACTCATCAAG GCCTACGGCA TCCGCTTCGA CATCATCGTG 
TTTGGAAAGG CTGGGAAGTT TGACATCATC CCTACCATGA TCAACATTGG CTCTGGCTTG GCGCTCTTAG GGGTGGCAAC AGTGCTGTGT GACGTCATAG 
TCCTCTACTG CATGAAGAAA AAATACTACT ATCGGGAGAA GAAATATAAA TATGTGGCAG ATTACGATCA GG 
P2X6 amplicon CAACTTCAGG ACAGCCACTC ACTGGAGGGA GGCCTCAGGC TTGGAGGCCC GGAGTCTGCT CAAACTCTAC GGGATCCGCT TCGACATCCT CGTCACTGGG 
CGGGCAGGGA AGTTCGGGCT CATCCCCACA ACCATCACTC TGGGCACTGG AGCGGCCTGG CTGGGTGTGA TCACCTTCTG CTGTGACCTG CTGCTGTTGT 
ACGTGGATGG AGAAGC 
P2X7 amplicon TTCCTACGTT ATCTTTGCCT TGGTGAGTGA CAAGCGGTAC CAGCGGAAAG AGCCTCTAAT CAGCTCTGTG CACACCAAGG TGAAAGGAAT AGCAGAGGTG 
AGAGAGGAGA TTATAGAGAG CGGAGCGAAG AAGGTGGTGC AGAGCGTCTT CGACACCGCA GACTACACC 
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Table 3.2. Nucleotide sequence alignement of P2X5 PCR amplicon to NCBI and Ensembl predicted equine P2X5 transcripts (XM_001918102.1, 
ENSECAT00000026624, ENSECAT00000026645, respectively). In areas of mismatches, matching sequences are noted in green and 
mismatching in red. 
eqP2X5 transcript Nucleotide sequence 
Ensembl26624 
Ensembl26645 
NCBI 
P2X5 amplicon 
ACCCCAGGGAGAGAACGTCTTCTTCATTGTCACCAACCTGATTGTGACCCCTAACCAGCGGCAGGGAACCTGTGCTGAGAGTGAAAACATCCCTGACGGCCTGTGCTATAAG 
ACCCCAGGGAGAGAACGTCTTCTTCATTGTCACCAACCTGATTGTGACCCCTAACCAGCGGCAGGGAACCTGTGCTGAGAGTGAAAACATCCCTGACGGCCTGTGCTATAAG 
ACCCCAGGGAGAGAACGTCTTCTTCATTGTCACCAACCTGATTGTGACCCCTAACCAGCGGCAGGGAACCTGTGCTGAGAGTGAAAACATCCCTGACGGCCTGTGCTATAAG 
---------------------------------------------------TAACCAGCGGCAGGGAACCTGTGCTGAGAGTGAAAACATCCCTGACGGCCTGTGCTATAAG 
                                                   ************************************************************* 
Ensembl26624 
Ensembl26645 
NCBI 
P2X5 amplicon 
GACAGCGACTGCCCTCCTGGGGAGCCTGTTGTGGCTGGAAATGGAGTGAAGACTGGCCGCTGCCTGCGGGCTGGGAAAATGCAAAGGG-CACCTGTGAGATCTTCG-----T 
GACAGCGACTGCCCTCCTGGGGAGCCTGTTGTGGCTGGAAATG---TGAAGACTGGCCGCTGCCTGCGGGCTGGGAAAATGCAAAGGG-CACCTGTGAGATCTTCG-----T 
GACAGCGACTGCCCTCCTGGGGAGCCTGTTGTGGCTGGAAATGGAGTGAAGACTGGCCGCTGCCTGCGGGCTG--AAAATGCAAAGGG-CACCTGTGAGATCTTCGCCTGAT 
GACAGCGACTGCCCTCCTGGGGAGCCTGTTGTGGCTGGAAATGGAGTGAAGACTGGCCGCTGCCTGCGGGCTGGGAAAATGCAAAGGGGCACCTGTGAGATCTTCGCCTGGT 
*******************************************   ***************************  ************* *****************     * 
Ensembl26624 
Ensembl26645 
NCBI 
P2X5 amplicon 
GCCCAGTGGAGACAAAGTCCAGGCCATCGAAGCCACTCCTGGGCAAGGCTGAAGACTTCACTGTTTACATAAAGAACTTCATTCGCTTCCCCAAATTCAACTTCTCCAAGAC 
GCCCAGTGGAGACAAAGTCCAGGCCATCGAAGCCACTCCTGGGCAAGGCTGAAGACTTCACTGTTTACATAAAGAACTTCATTCGCTTCCCCAAATTCAACTTCTCCAAGAC 
GCCCAGTGGAGACAAAGTCCAGGCCATCGAAGCCACTCCTGGGCAAGGCTGAAGACTTCACTGTTTACATAAAGAACTTCATTCGCTTCCCCAAATTCAACTTCTCCAAGAC 
GCCCAGTGGAGACAAAGTCCAGGCCATCGAAGCCACTCCTGGGCAAGGCTGAAGACTTCACTGTTTACATAAAGAACTTCATTCGCTTCCCCAAATTCAACTTCTCCAAGAC 
**************************************************************************************************************** 
Ensembl26624 
Ensembl26645 
NCBI 
P2X5 amplicon 
CAATGTGCTGGACACCGAAGACAGATCTTACCTGAAGTTCTGTCAATTTGACCCCAAGAACCTCTACTGCCCCATCTTCCGAGTGGGGTCCTTGGTCAGCTGGGCGGGGAGC 
CAATGTGCTGGACACCGAAGACAGATCTTACCTGAAGTTCTGTCAATTTGACCCCAAGAACCTCTACTGCCCCATCTTCCGAGTGGGGTCCTTGGTCAGCTGGGCGGGGAGC 
CAATGTGCTGGACACCGAAGACAGATCTTACCTGAAGTTCTGTCAATTTGACCCCAAGAACCTCTACTGCCCCATCTTCCGAGTGGGGTCCTTGGTCAGCTGGGCGGGGAGC 
CAATGTGCTGGACACCGAAGACAGATCTTACCTGAAGTTCTGTCAATTTGACCCCAAGAACCTCTACTGCCCCATCTTCCGAGTGGGGTCCTTGGTCAGCTGGGCGGGGAGC 
**************************************************************************************************************** 
Ensembl26624 
Ensembl26645 
NCBI 
P2X5 amplicon 
AACTTCCAGGACATAGCCCTGCAGGGTGGTGTGATAGGAATTCAGATTGAATGGGACTGTGATCTTGATAAAGCTCCCTCCGAATGCA 
AACTTCCAGGACATAGCCCTGCAGGGTGGTGTGATAGGAATTCAGATTGAATGGGACTGTGATCTTGATAAAGCTCCCTCCGAATGCA 
AACTTCCAGGACATAGCCCTGCAGGGTGGTGTGATAGGAATTCAGATTGAATGGGACTGTGATCTTGATAAAGCTCCCTCCGAATGCA 
AACTTCCAGGACATAGCCCTGCAGGGTGGTGTGATAGGAATTCAGATTGAATGGGACTGTGATCTTGATAAAGCTCCCTCCGAATGCA 
**************************************************************************************** 
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Table 3.3. Alignment of equine P2X5 translated amplicon amino acid sequence 
against the NCBI and Ensembl predicted P2X5 amino acid sequences 
(XP_001918137, ENSECAP00000022228 (transcript ENSECAT00000026624), 
ENSECAP00000022248 (transcript ENSECAT00000026645), respectively) for the 
transcript region containing the mismatches. In areas of mismatches, matching 
sequences are highlighted in green and mismatching in red. 
Equine P2X5 protein Location Amino acid sequence 
translated amplicon sequence 
NCBI       XP_001918137 
Ensembl  ENSECAP00000022228 
Ensembl  ENSECAP00000022248 
 
112-149 
89-126 
89-125 
CPPGEPVVAGNGVKTGRCLRAGKMQRGTCEIFAWCPVET 
CPPGEPVVAGNGVKTGRCLRA-ENAKGTCEIFA-CPVET 
CPPGEPVVAGNGVKTGRCLRAGKMQR--APVRSSCPVET 
CPPGEPVVAGN-VKTGRCLRAGKMQR--APVRSSCPVET 
*********** *********             ***** 
 
 
3.3.2 P2X1-7 protein Western blot analysis 
 
Western blot analysis revealed protein bands around the expected size for 
P2X1-3, 7 proteins (55, 42, 50, and 79 kDa, respectively) in all sampled tissues 
(Figure 3.2a, Table 3.4). P2X1 and P2X7 protein Western blots also showed 
secondary protein bands at higher molecular weights (110 kDa and ~170 kDa, and 
110 kDa and 140 kDa, respectively) (Figure 3.2a). Expression of higher molecular 
weight bands is recognised in P2X receptor expression analysis where dimer and 
trimer formation occurs (Jiang et al. 2005). Control experiments with pre-incubation 
of P2X1 and P2X7 receptor antibodies with their immunogen peptide resulted in a 
reduction in the intensity of the protein bands confirming P2X1 and P2X7 receptor 
antibody specificity to the peptide (Figure 3.2b). 
Antibody specificity for P2X4, P2X5, and P2X6 receptor antibodies could 
not be confirmed as their Western Blots showed multiple bands at molecular weights 
other than the expected for each protein. The Western blots with P2X4 receptor 
antibodies (Abcam, Alomone) revealed a multitude of bands at different molecular 
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weights other than the expected band (43 and 50 kDa, respectively). P2X5 receptor 
Western blot showed a band around the expected size (50 kDa) along with a strong 
band at a smaller molecular weight which was not attenuated after preincubation of 
P2X5 receptor antibody with its immunogen peptide. The Western blot with P2X6 
receptor antibody revealed a band around the expected size (48 kDa) in nervous 
tissue but bands at higher molecular weights that did not follow the same pattern 
were also present. 
Mass spectrometry was used as an additional tool to confirm the identity of 
the P2X protein bands. However, the results of the mass spectrometry analysis of the 
excised bands did not show the presence of P2X receptor proteins but other proteins 
present in the sampled tissues (Table 3.5). So, with mass spectrometry not being able 
to confirm the presence of P2X receptor subtype proteins, the identification of P2X 
protein bands in Western Blots was based on their size and control experiments. 
 
 
Table 3.4. Predicted MW for equine P2X1-3, 7 receptor subtype proteins, antibody 
manufacturer documented MW for P2X1-3, 7 proteins, and observed MW for equine 
P2X1-3, 7 receptor subtype proteins in analysed samples (along with the accession 
number of equine predicted P2X1-3, 7 receptor proteins). 
P2X receptor 
subtype 
Predicted 
MW (kDa) 
Antibody datasheet 
MW (kDa) 
WB protein 
band MW 
(kDa) 
Accesion number 
(NCBI, Ensembl) 
P2X1 45 50 and 52 (human) 55 XP_001504780 
P2X2 39 40 (human) 42 ENSECAP00000014190 
P2X3 44 50 (and 75) (rat) 50 XP_001504964 
P2X7 69 70 (and 120) (human) 79 XP_001495622 
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Figure 3.2. (a) Western blot analysis for P2X1-3, 7 proteins showing validation of 
P2X1-3, 7 antibodies against equine homologues. Shown are representative bands of 
Western blots for P2X1-3, 7 proteins in equine tissue samples lysates (P2X1 palmar 
digital artery lysate, P2X2 and P2X3 C8 DRG lysate, P2X7 hoof lysate). The bands 
observed at 55, 42, 50 and 79 kDa represent P2X1-3, 7 proteins, respectively, 
whereas the bands observed at higher molecular weights correspond to the protein’s 
glycosylated form or multimer. (b) Western blot analysis for P2X1 and P2X7 
antibodies (palmar digital vein lysate) with and without preincubation with the 
immunogen peptide. Note the significant reduction in band intensities for P2X1 
(55kDa) and P2X7 (79 kDa) receptor subtype proteins following pre-incubation with 
the immunogen peptide. 
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Table 3.5. Mass spectrometry results, top hits. 
 Top hits Function Sample 
Band 1 actin, aortic smooth 
muscle isoform 1 
major constituent of contractile 
apparatus 
p. d. artery 
 filamin-A like crosslinks actin filaments in 
orthogonal networks in cortical 
cytoplasm and links actin 
filaments to membrane 
glycoproteins 
 
 thymidine phosphorylase-
like 
catalyzes the reversible 
phosphorolysis of thymidine, 
promotes angiogenesis 
 
Band 2 glial fibrillary acidic 
protein 
intermediate filament protein 
(type III) 
hoof 
 septin-7 filament-forming cytoskeletal 
GTPase, involved in cytokinesis 
 
 calreticulin-like associated with the endoplasmic 
reticulm 
 
Band 3 serum albumin blood plasma protein spinal cord 
 fructose-biphosphate 
aldolase 
key role in glycolysis and 
gluconeogenesis 
 
 vimentin intermediate filamen protein (type 
III), major cytoskeletal 
component of mesenchymal cells 
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3.3.3 P2X1-3, 7 receptor subtype immunohistochemical analysis 
 
Palmar digital artery and vein 
Figure 3.3 shows the distribution of P2X1-3, 7 receptor subtype proteins in 
palmar digital artery and vein. P2X1, 2, 7 receptor subtype proteins were 
demonstrated in the smooth muscle cells in the tunica media of the palmar digital 
artery and vein whereas P2X3 receptor subtype positive staining was identified in 
smooth muscle cells of the vein but not the artery. P2X7 receptor subtype staining in 
smooth muscle cells exhibited characteristic patterning, being localised in a thin line 
adjacent to the nucleus. Palmar digital artery and vein endothelial cells were 
immunopositive for P2X2 receptor subtype whereas only palmar digital vein 
endothelial cells were immunopositive for P2X3 receptor subtype. 
 
Hoof 
In the equine hoof, P2X1-3 receptor subtype staining predominately occurred 
in epidermal basal cells. Additionally, P2X1 and P2X2 receptor subtype staining was 
seen in the dermis capillaries and small vessels. P2X7 receptor subtype staining was 
present in the epidermal basal cells and in corium fibroblasts (Figure 3.4). 
 
Palmar digital nerve 
In the palmar digital nerve, P2X1 and P2X2 receptor subtype staining was 
mostly present in nerve fibres and to a lesser extent in Schwann cells (Figure 3.5). 
P2X3 receptor subtype staining was present only in nerve fibres and P2X7 receptor 
subtype staining was seen exclusively in Schwann cells. 
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Dorsal root ganglia and spinal cord 
In C4 and C8 DRG, P2X1 receptor subtype staining was seen mainly in 
neurons and faintly in satellite glial cells. P2X2 receptor subtype staining, in 
comparison, was present in both DRG neurons and satellite glial cells. P2X3 receptor 
subtype staining was present in DRG neurons only whereas P2X7 receptor subtype 
staining was strong in DRG Schwann cells (Figure 3.6). 
In C4 and C8 spinal cord segments, P2X1-3, 7 receptor subtype staining was 
present in dorsal horn neurons and ependymal cells with P2X3 receptor subtype 
staining strongest in neuronal cell body and projections. P2X1, 2, 7 receptor subtype 
staining was also present in dorsal horn glial cells (Figure 3.7). 
 
No staining was observed in control experiments with omission of the 
primary antibody and substitution of the primary antibody with non-immune rabbit 
polyclonal IgG (Figure 3.8 and 3.9). 
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Figure 3.3. Immunostaining for P2X1 (a, e), P2X2 (b, f), P2X3 (c, g) and P2X7 (d, h) 
receptor subtypes in equine palmar digital artery (a-d) and vein (e-h). (a, e) P2X1 receptor 
subtype was present in the smooth muscle cells in the tunica media of the palmar digital 
artery (a) and vein (e). Insert shows representative image of positive smooth muscle cells. (b, 
f) P2X2 receptor subtype was present in the smooth muscle cells in the tunica media and the 
endothelial cells of the palmar digital artery (b) and vein (f). Insert shows representative 
image of positive endothelial and smooth muscle cells. (c, g) P2X3 receptor subtype was not 
found in the palmar digital artery (c) but was present in the smooth muscle cells in the tunica 
media and the endothelial cells of the palmar digital vein (g). Insert shows representative 
image of endothelial and smooth muscle cells. (d, h) P2X7 receptor subtype was present in 
the smooth muscle cells in the tunica media of the palmar digital artery (d) and vein (h). 
Insert shows representative image of P2X7 receptor subtype staining in smooth muscle cells. 
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Figure 3.4. Immunostaining for P2X1 (a), P2X2 (b), P2X3 (c) and P2X7 (d) receptor 
subtypes in equine hoof. P2X1-3, 7 receptor subtypes staining predominately 
occurred in epidermal basal cells. Inserts show representative images of positive 
epidermal basal cells. 
 
96 
 
 
 
 
 
 
 
Figure 3.5. Immunostaining for P2X1 (a), P2X2 (b), P2X3 (c) and P2X7 (d) receptor 
subtypes in equine palmar digital nerve. (a, b) P2X1 (a) and P2X2 (b) receptor 
subtype staining was strong in nerve fibres but faint in Schwann cells. Inserts show 
representative images of positive Schwann cells and nerve fibre. (c) P2X3 receptor 
subtype staining was present only in nerve fibres. Insert shows representative image 
of a positive nerve fibre. (d) P2X7 receptor subtype staining was seen exclusively in 
Schwann cells. Insert shows representative image of longitudinal section of positive 
Schwann cells myelin sheath. 
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Figure 3.6. Immunostaining for P2X1 (a, e), P2X2 (b, f), P2X3 (c, g) and P2X7 (d, h) 
receptor subtypes in equine C4 (a-d) and C8 (e-h) DRG. (a, e) P2X1 receptor subtype 
staining was strong in DRG neuronal cells but faint in satellite glial cells in C4 (a) 
and C8 (e) DRG. Insert shows representative image of positive neurons and satellite 
glial cells. (b, f) P2X2 receptor subtype staining was present in both DRG neurons 
and satellite glial cells in C4 (b) and C8 (f) DRG. Insert shows representative image 
of positive neurons and satellite glial cells. (c, g) P2X3 receptor subtype staining was 
present only in DRG neurons in C4 (c) and C8 (g) DRG. Insert shows representative 
image of positive neurons. (d, h) P2X7 receptor subtype staining was strong in 
Schwann cells in C4 (d) and C8 (h) DRG. Insert shows representative image of 
positive Schwann cells myelin sheaths. 
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Figure 3.7. Immunostaining for P2X1 (a, e), P2X2 (b, f), P2X3 (c, g) and P2X7 (d, h) 
receptor subtypes in equine C4 (a-d) and C8 (e-h) spinal cord segments. (a, e) P2X1 
receptor subtype was present in dorsal horn neurons (a1 and e1) and glial cells (inserts 
a2 and e2) in C4 and C8 spinal cord segments. (b, f) P2X2 receptor subtype was 
present in dorsal horn neurons (b1 and f1) and glial cells (inserts b2 and f2) in C4 and 
C8 spinal cord segments. (c, g) P2X3 receptor subtype staining was strong in dorsal 
horn neurons cell body and projections (c1 and g1) but absent in glial cells (inserts c2 
and g2) in C4 and C8 spinal cord segments. (d, h) P2X7 receptor subtype was present 
in dorsal horn neurons (d1 and h1) and glial cells (inserts d2 and h2) in C4 and C8 
spinal cord segments. 
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Figure 3.8. Immunohistochemistry control with the omission of primary antibody for 
palmar digital artery (a), palmar digital vein (b), palmar digital nerve (c), hoof (d), 
C4 dorsal root ganglion (e), C8 dorsal root ganglion (f), C4 spinal cord segment (g) 
and C8 spinal cord segment (h). No immunostaining was observed in each of the 
tissue types. 
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Figure 3.9. Immunohistochemistry control with substitution of primary antibody with 
non-immune rabbit IgG for palmar digital artery (a), palmar digital vein (b), palmar 
digital nerve (c), hoof (d), C4 dorsal root ganglion (e), C8 dorsal root ganglion (f), 
C4 spinal cord segment (g) and C8 spinal cord segment (h). No immunostaining was 
observed in each of the tissue types. 
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3.4 Discussion 
 
Purinergic P2X receptors have been identified in both excitable and non-
excitable cells and have important roles in neuronal transmission and regulation as 
well as cell growth, differentiation and survival (Neary & Burnstock 1996, 
Abbrachio et al. 2009, Burnstock & Verkhratsky 2010). In this chapter, the presence 
of P2X1-7 receptor subtypes was identified in equine tissue, specifically the hoof and 
its vasculature and innervation. Also, the location and distribution of four key 
receptor subtypes (P2X1-3, 7) was demonstrated in these tissues, showing important 
differences in cellular location and suggesting that heterogeneity in receptor 
expression may be important in normal cellular and tissue function. 
 
PCR experiments identified gene expression (mRNA) for all seven P2X 
receptor subtypes in equine tissues. mRNA signal of P2X1-7 receptor subtypes was 
found in all sampled tissues supporting previous findings of widespread P2X gene 
expression throughout mammalian tissues (review Burnstock & Knight 2004). 
The PCR amplicons were sequenced and the nucleotide sequences matched 
the predicted ones for P2X1-4, 6-7 receptor mRNA (NCBI and Ensembl). The P2X5 
amplicon was found to combine parts of sequences matching the NCBI predicted 
transcript, the Ensembl predicted transcripts or neither NCBI/Ensembl predicted 
transcripts. The mismatches between P2X5 amplicon nucleotide sequence and NCBI 
and Ensembl predicted nucleotide sequences did not result in interruption or 
alteration of the transcript’s reading frame. However, translation of the codons 
containing the mismatches and alignment against the predicted amino acid sequences 
revealed differences in the amino acid sequences, either due to predicted sequences 
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inaccuracy or the existence of equine P2X5 protein splice variants. Future work 
including the amplification and sequencing of the full equine P2X5 transcript length 
from several animals and different tissues may help elucidate the existence of equine 
P2X5 protein splice variants. 
DNA sequencing did not reveal any tissue-related differences in P2X1-7 
amplicons’ nucleotide sequences in the samples. Expression of splice variants in 
tissues though has been documented for P2X receptors and they may account for the 
heterogeneity of P2X responses in tissues in health and disease (Carpenter et al. 
1999, Lynch et al. 1999, Mankus et al. 2011). The absence of P2X splice variants in 
the samples in the present study (despite the wide range of tissues examined) could 
be attributed to the analysis of a small part of the P2X receptor transcripts as opposed 
to the full transcript length. This is the first report of eqP2X1-7 cDNA sequencing 
and P2X1, 3-6 receptor subtype partial cds have been deposited in NCBI database for 
future reference (accession KC790392 to KC790396, respectively). 
 
After mRNA signal was detected in equine tissue, Western blot analysis was 
used to investigate protein expression in the same tissues and validate the use of P2X 
receptor antibodies in equine tissue. Antibodies raised against equine P2X1-7 
receptor subtype proteins are not commercially available and therefore antibodies 
raised against other species were selected based on the homology of their 
immunogen peptide amino acid sequence to the respective equine predicted amino 
acid sequence. P2X receptor proteins show high inter-species similarity, reaching up 
to 99% (Volonté et al. 2006). Here, the amino acid sequences of the selected 
antibodies (immunogen peptides) and the predicted equine P2X receptor proteins 
showed high similarity (83.33-100%) for the antibodies whose specificity in equine 
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tissue was validated (P2X1-3, 7) and lower (42.11-78.57%) for the other antibodies 
(P2X4-6) (see Table 2.4). 
Antibody specificity was validated for P2X1-3, 7 receptor antibodies and 
P2X1-3, 7 receptor subtype proteins presence was observed in all sampled tissues. 
P2X4-6 receptor antibodies’ specificity could not be confirmed with the Western 
Blot experiments and they were not used in subsequent experiments. However, 
P2X4-6 receptor subtypes protein presence and distribution in equine tissue presents 
some interest with regards to laminitis and chronic laminitic pain. P2X4 receptor 
subtype has been suggested to participate in chronic pain states by instigating pain 
hypersensitivity through its activity on spinal microglia and peripheral macrophages 
(review Trang & Salter 2012). Similarly, P2X6 receptor subtype is widespread in the 
nervous system (Collo et al. 1996) and could participate in the modulation of 
neurotransmission contributing to the pain state present in equine laminitis. Finally, 
P2X5 receptor subtype participation in keratinocyte differentiation (Greig et al. 
2003) could help understand the events occuring in the equine hoof in laminitis. 
Therefore, additional P2X4-6 receptor antibodies targeting different protein epitopes 
with higher inter-species similarity should be tested in the future to achieve 
validation of their use in equine tissue. 
Some discrepancy between actual and predicted molecular weights for bands 
was present in P2X1-3, 7 blots (Table 3.4) and is most likely explained by 
glycosylation and other post-translational modifications occurring in P2X proteins 
(North 2002, Jiang et al. 2005), prediction errors (see P2X5 mRNA), and/or inter-
species differences (antibody datasheet MW). Also, some Western blots (P2X1 and 
P2X7) revealed bands of higher molecular weight in addition to the main band at the 
expected size. P2X receptor protein expression analysis has demonstrated dimer and 
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trimer formation resulting in Western blot bands of higher molecular weight (Jiang et 
al. 2005). Where results showed bands of molecular weight higher than expected 
(P2X1 and P2X7), control experiments with immunogen peptide pre-incubation 
confirmed the bands’ identity. Mass spectrometry analysis was undertaken to attempt 
to determine the identity of the bands seen in Western blot experiments. The results, 
however, showed the presence of other proteins and did not confirm the presence of 
P2X receptor subtype proteins in the analysed bands. Although mass spectrometry is 
one of the most powerful proteomic tools and has been used successfully for 
identification and quantification of proteins, Western blotting techniques can be more 
sensitive, especially for low-abundance proteins (Diamandis 2004). P2X receptor 
subtype proteins identity was, therefore, based on Western blot experiments. 
 
In the immunohistochemical analysis, palmar digital artery and vein smooth 
muscle cells showed staining for P2X1, P2X2 and P2X7 receptor subtypes whereas 
P2X3 receptor subtype was present in smooth muscle cells in vein but not artery. 
P2X1 receptor subtype is the predominant receptor subtype in vascular smooth 
muscle cells but smooth muscle cells have been found to express a range of different 
P2X receptor subtypes, including the P2X2, P2X3 and P2X7 receptor subtypes as 
found in this study (Cario-Toumaniantz et al. 1998, Nori et al. 1998, Hansen et al. 
1999, Lewis & Evans 2001). In addition to the wide range of P2X receptor subtypes 
expressed in smooth muscle cells, the relative expression of these subtypes varies 
both in different vascular beds and vessels of different calibre in the same vascular 
bed accounting, in part, for the magnitude in P2X receptor-mediated responses 
between different vessels (Lewis & Evans 2001). Functionally, P2X receptors on 
vascular smooth muscle cells have been linked to a vasoconstrictor role (Harrington 
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& Mitchell 2004), especially in small arteries (Gitterman & Evans 2001). However, 
P2X receptor subtypes are also expressed on endothelium where they mediate 
vasodilation (Harrington & Mitchell 2004). Here, vascular endothelial cells were 
positive for P2X2 receptor subtype in palmar digital artery and P2X2 and P2X3 
receptor subtype in palmar digital vein. P2X2 and P2X3 receptor subtypes have also 
been described in vascular endothelial cells in other studies (Hansen et al. 1999, 
Glass et al. 2000, Loesch & Burnstock 2000, Glass & Burnstock 2001) along with 
other receptor subtypes (P2X4, P2X5) (Schwiebert et al. 2002) and could regulate 
vasoactive substance release in endothelial cells following activation by extracellular 
ATP after local hypoxia and haemodynamic changes, such as shear stress (Bodin et 
al. 1991, Bergfeld & Forrester 1992, Schwiebert et al. 2002). 
Hoof epidermal basal cells were positive for P2X1, P2X2, P2X3 and P2X7 
receptor subtypes. P2X receptor expression and distribution in the equine hoof has 
not been previously described. The equine hoof shares a common basic structure 
with skin but hoof epidermal cells have evolved as a highly modified epidermal layer 
to enable it to function in its roles within the suspensory apparatus of the distal 
phalanx in Equids (Bragulla & Hirschberg 2003). Previous studies in human and rat 
skin keratinocytes have reported the presence of P2X2, P2X3, P2X5 and P2X7 
receptor subtypes. P2X receptors found in skin are suggested to have an important 
physiological role as initial sensors for external stimuli and P2X7 receptors, known 
to be involved in ATP-induced apoptosis, are likely to participate in the process of 
the end-stage terminal differentiation of keratinocytes (Inoue et al. 2005). The 
expression of P2X receptor subtypes in epidermal basal cells suggests a potential role 
for P2X receptors in relation to cell growth and differentiation in the equine hoof. 
This finding may have important implications in clinical conditions of the hooves, 
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such as laminitis, where destruction of the epidermal-dermal interface occurs, 
resulting in catastrophic mechanical failure of the hoof and extreme pain (Pollitt 
1996). 
P2X receptor expression and function in peripheral nerve has been 
extensively studied in other species (for review see Dunn et al. 2001) and P2X2 and 
P2X3 receptor subtype immunoreactivity has been documented in peripheral nerve 
terminals (Vulchanova et al. 1998, Bo et al. 1999). In this study, the palmar digital 
nerve fibres were positive for P2X1, P2X2, and P2X3 receptor subtypes. Agonist 
studies show that C-fibre nociceptors show the greatest response to extracellular 
nucleotide activation, suggesting a predominately nociceptive role for P2X receptors 
(Hamilton & McMahon 2000). However, the palmar digital nerve of the horse also 
includes efferent autonomic neurons involved in local vascular responses (Molyneux 
et al. 1994), suggesting pain transmission might not be the only role for purinergic 
receptors in nerve fibres (Bo et al. 1999). Additionally, Schwann cells in sampled 
palmar digital nerve showed strong staining for P2X7 receptor subtype and faint 
staining for P2X1 and P2X2 receptor subtypes. Expression of the P2X7 receptor has 
also been reported in human and mouse Schwann cells where it may be involved in 
local immunomodulation of axonal function by Schwann cells including regulation 
of cytokine release (Colomar & Amédée 2001, Chessell et al. 2005); this may be of 
particular relevance during peripheral nerve injury or neuropathies (Scholz & Woolf 
2007). 
In DRG, neurons were stained for P2X1, P2X2 and P2X3 receptor subtypes. 
Although, P2X3 is the predominant subtype reported in DRG neurons, variable 
levels of immunoreactivity for P2X1-2 and P2X4-6 receptor subtypes have also been 
detected, with evidence of heteromultimerisation of P2X2 and P2X3 receptor 
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subtypes (Vulchanova et al. 1997, Xiang et al. 1998, Barden & Bennett 2000). In rats 
DRG, P2X3 staining is predominantly found in a subset of small and medium 
diameter neurons, with a nociceptive function, while it is absent from most large 
neurons (Chen et al. 1995, Bradbury et al. 1998, Barden & Bennett 2000). In 
contrast, P2X2 receptor subtype immunoreactivity is reported in small and medium 
as well as in large diameter neurons (Barden & Bennett 2000). Here, P2X1, P2X2 
and P2X3 receptor subtype staining was seen in all small, medium, and large 
neurons. Similarly to the findings in the present study, P2X3 receptor subtype 
immunoreactivity in rat trigeminal ganglia is also found in large neurons (Cook et al. 
1997). The highly selective distribution of P2X3 and P2X2/3 receptors within the 
nociceptive system suggests a role for these receptors in pain pathways and studies 
showing alterations in P2X3 receptor expression in pain models have highlighted the 
importance of these receptors in different pain states (North 2004, Wirkner et al. 
2007). Whereas P2X3 receptor subtype immunoreactivity in DRG was seen only in 
neurons, P2X2, and to a lesser degree P2X1, receptor subtype staining was also 
present in satellite glial cells. P2X2 receptor subtype immunoreactivity is also 
documented in rat DRG satellite glial cells (Vulchanova et al. 1997). Indeed, all 
types of glia are known to express purinergic receptors and a role for ATP in neuron-
glial communication (beyond homeostasis of the extracellular environment 
surrounding neurons, including regulating synaptic strength, gene expression, mitotic 
rate and differentiation of glia) has been established with a particular interest in a 
role in the development of neuropathic pain (see Fields & Stevens 2000, Scholz & 
Woolf 2007). Finally, P2X7 receptor subtype immunoreactivity in the equine DRG 
was localised to the DRG Schwann cells, similarly to the distribution observed in the 
equine palmar digital nerve and to findings in rat DRG (Zhang et al. 2005). P2X7 
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receptor in glia has been shown to participate in inflammatory and neuropathic 
hypersensitivity with a critical role in glia-neuronal signalling and may have 
profound effects on neuronal function under injured or diseased states (Chessell et al. 
2005, Zhang et al. 2005). 
In spinal cord, dorsal horn neurons were found positive for P2X1-3, 7 
receptor subtypes. mRNA for all seven P2X receptor subtypes have been found in 
the spinal cord dorsal horn (Nakatsuka & Gu 2006) and findings consistent with the 
expression of P2X2-4 and P2X6-7 receptor subtypes in dorsal horn neurons have 
been documented, especially in lamina II (Bardoni et al. 1997, Llewellyn-Smith & 
Burnstock 1998, Kanjhan et al. 1999, Deuchars et al. 2001). The lamina II in the 
spinal cord is a region known to receive strong input from nociceptive primary 
afferents and release of ATP is known to modulate neurotransmitter release, such as 
glutamate through P2X receptors in central afferent terminals or second-order 
neurons of the spinal cord, suggesting a role for P2X receptors in transmitting or 
modulating nociceptive information in the central nervous system (Bardoni et al. 
1997, Chizh & Illes 2001). However, ATP has also been shown to facilitate glycine- 
(Rhee et al. 2000) and GABAergic (Hugel & Schlichter 2000) spontaneous 
inhibitory postsynaptic currents at dorsal horn synapses through P2X receptors thus 
inhibiting nociceptive transmission. This suggests that a fine balance of excitatory 
and inhibitory components of purinergic transmission in the spinal cord may exist 
under normal conditions (Chizh & Illes 2001). The spinal cord glial cells in the 
samples in the present study were positive for P2X1, P2X2 and P2X7 receptor 
subtypes. In other species, P2X2 and P2X7 receptor subtypes have been reported in 
spinal cord astrocytes and oligodendrocytes, respectively (Matute 2008, Verkhratsky 
et al. 2012). P2X4 and P2X7 receptor subtypes are also present in spinal microglia 
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where P2X7 participates in microglial activation and secretion of proinflammatory 
factors and P2X4 in the development of allodynia in neuropathic pain (Morioka et al. 
2008, Verkhratsky et al. 2012). The development of pathologic pain involves not 
only neuronal pathways but also glial signalling (see Scholz & Woolf 2007, Cao & 
Zhang 2008) and P2X receptors may have a key role in it (Chessell et al. 2005, 
Verkhratsky et al. 2012). 
 
This is the first report of P2X receptor expression and distribution in equine 
tissue, with particular emphasis on the equine fore limb hoof and associated 
vasculature and nerve supply (Zamboulis et al. 2013). Equine P2X1-7 receptor 
transcripts and proteins were identified in these tissues and the distribution of four 
key members of the P2X receptor family, P2X1-3, 7, was detailed, showing 
important differences in tissue distribution and suggesting that heterogeneity in 
receptor expression may be important in normal cellular and tissue function. 
Additionally, the equine P2X1-7 receptor mRNA nucleotide sequences were 
partially annotated and the use of P2X1-3, 7 receptor antibodies in equine tissue was 
validated. P2X4-6 receptor antibodies specificity in equine tissue could not be 
validated here. However, more antibodies should be tested in the future, as P2X4-6 
receptor subtypes may have a role in the chronic pain state associated with laminitis 
and the changes occuring in the laminitic equine hoof. 
The widespread distribution of P2X receptor subtypes in the equine hoof and 
associated vasculature and nerve supply along with their implication in cellular 
processes in health and disease may highlight a potential role for them in the 
regulation of the normal structure and function of the hoof and in hoof related pain 
pathways. 
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Chapter 4 
 
Expression of purinergic P2X1-3 and 7 receptor 
subtypes in equine laminitis 
 
(work accepted for publication under the title “Expression of purinergic P2X receptor 
subtypes 1, 2, 3 and 7 in equine laminitis” Zamboulis et al. (2013) The Veterinary 
Journal doi: http://dx.doi.org/10.1016/j.tvjl.2013.08.017) (see Appendix for full text) 
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4.1 Introduction 
 
Laminitis in horses is manifested by disruption of the lamellar suspensory 
apparatus of the distal phalanx, with loss of mechanical support and associated pain 
(Pollitt 2011) with pain being a predominant feature of the condition. Following the 
development of acute laminitis, up to 75% of horses may develop a protracted form 
of the disease, resulting in chronic debilitation and eventual mortality (Moore 2009). 
In the horse, tissue sensitisation and chronic pain states have been documented in 
joint disease and laminitis (Malone 2002, Jones et al. 2007). Characterisation of 
pathways involved in tissue sensitisation and chronic pain may reveal new 
therapeutic targets (Heinzmann & McMahon 2011). 
There is a growing body of evidence linking P2X receptors to chronic pain 
and inflammation in other species (Gu & Heft 2004, Chessell et al. 2005). Changes 
in P2X3 and P2X7 receptor subtypes expression in the dorsal root ganglia and spinal 
cord have been implicated in the development of neuropathic pain in rats (Xiang et 
al. 2008, He et al. 2012). Furthermore, functional studies with the use of P2X3 
receptor antisense oligonucleotides, antagonists, and knockout mice confirm the 
involvement of the P2X3 channel in neuropathic pain (Barclay et al. 2002, Honore et 
al. 2002, Jarvis et al. 2002, Sharp et al. 2006). Similarly, functional studies involving 
P2X7 receptor antagonists and knockout mice reveal a role for P2X7 receptor in 
chronic inflammatory and neuropathic pain (Chessell et al. 2005, Honore et al. 
2006). In addition, endogenous ATP release by epithelial and endothelial cells occurs 
in response to local tissue changes, such as hypoxia and acidosis, altering cell 
proliferation and survival (Burnstock & Verkratsky, 2010). 
In chapter 3, P2X receptor subtype expression in the normal horse was 
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examined. Here, previous observations were extended to include naturally occurring 
chronic active laminitis. The aim of this chapter was to investigate altered P2X 
receptor subtype expression in the hoof, palmar digital vessels and nerve, dorsal root 
ganglia and spinal cord in horses with chronic active laminitis compared to non-
laminitic horses. For this purpose, immunohistochemistry experiments were carried 
out in tissues collected from horses suffering from chronic active laminitis and 
P2X1-3, 7 receptor subtypes distribution and expression was compared to that of 
normal horses. In addition, the histology of H&E stained tissues from chronic 
laminitic horses was assessed and compared to that of normal horses to investigate 
the correlation of altered P2X receptor expression with morphological changes in the 
examined tissues. 
 
 
4.2 Study design 
 
• Sample collection – Tissue samples were collected from euthanased horses  
(n = 5, mean age 14 years) suffering from naturally occurring chronic active 
laminitis (in accordance with Pollitt & Collins 2011). Horses had a duration 
of chronic laminitis ranging from 1-15 months with time of onset of laminitis 
defined as the first recorded event of laminitis by the owner and/or 
veterinarian (Table 4.1). The cause of laminitis was not determined here as 
the main focus was pain in relation to chronicity of the condition and the 
cases were solely defined by duration of the condition. Sampled tissues 
included the palmar digital artery, palmar digital vein, palmar digital nerve, 
hoof, ipsilateral C8 DRG and spinal cord (innervating the hoof) and 
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ipsilateral C4 DRG and spinal cord (not innervating the hoof) (see 2.1 
Samples p.35). 
 
Table 4.1. Ages and duration of laminitis for horses suffering from chronic laminitis. 
Case Age (years) Duration of chronic 
laminitis (months) 
Case 1 13 1 
Case 2 12 1 
Case 3 13 8 
Case 4 17 10 
Case 5 15 15 
 
 
• Histologic evaluation of tissues samples from horses with chronic 
laminitis – Sampled tissue sections from horses suffering from chronic 
laminitis were stained with H&E and assessed descriptively. The thickness of 
the tunica media in the palmar digital artery and vein was measured and 
expressed as ratio of overall vessel thickness. Histopathological changes in 
the hoof were described as mild, moderate or severe (were graded as 1 (mild), 
2 (moderate), 3 (severe)) according to Hampson et al. (2012). Neuronal cell 
body size in C4 and C8 DRG was measured and defined as small (<30 µm), 
medium (30-60 µm), and large (>60 µm) according to Holford et al. (1994) 
and their distribution determined (see 2.4.2 Histology p.55). 
 
• Characterisation of P2X1-3, 7 receptor subtype proteins distribution in 
chronic laminitic horses – P2X1-3, 7 antibodies validated in equine tissue in 
Chapter 3 were used for immunohistochemical characterisation of their 
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respective proteins’ distribution in sampled tissues from horses suffering 
from chronic laminitis (see 2.4.3 Immunohistochemistry p.56). 
 
• Comparison of P2X1-3, 7 receptor subtype distribution and expression 
between chronic laminitic and normal horses – P2X1-3, 7 receptor subtype 
distribution was compared between chronic laminitic and normal horses and 
semi-quantitative immunohistochemistry was used to compare the expression 
levels (staining intensity) of two key P2X receptor subtypes in chronic pain, 
P2X3 and P2X7, between chronic laminitic and normal horses. For semi-
quantitative immunohistochemistry, representative fields of view (n = 5) in 
immunostained sections were randomly selected for semi-quantification and 
mean grey scale intensity was measured after correction for white balance. 
Staining intensity for P2X3 receptor subtype in C8 DRG for each laminitic 
case was normalised against the staining intensity in the C4 DRG of the same 
horse and expressed as a ratio to the average normalised staining intensity of 
the C8 DRG in normal horses. Staining intensity for P2X7 receptor subtype 
in C4 and C8 DRG was normalised to DRG neuron nucleus counterstain (see 
2.4.4 Semi-quantitative immunohistochemistry p.60). 
 
• Statistical analysis – Data were tested for Normality using the Shapiro-Wilk 
test and significant differences were determined with Student’s t test. For 
correlation analysis of hoof changes vs. time, the Pearson correlation 
coefficient (r) was calculated. The level of significance was set at P < 0.05 
and data were presented as mean ± SD (see 2.8 Statistical analysis p.79). 
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4.3 Results 
 
4.3.1 Histological findings 
 
The histological evaluation of chronic laminitic tissues in comparison to 
normal revealed several findings. The morphometric examination of the palmar 
digital artery and vein revealed a significant reduction in the thickness of the tunica 
media in the palmar digital vein of horses with laminitis (0.48 ± 0.05, n = 5) 
compared to unaffected horses (0.57 ± 0.04, n = 5, P = 0.02). No difference was 
observed in the thickness of the tunica media in the palmar digital artery of horses 
with laminitis and normal horses (0.52 ± 0.05, 0.57 ± 0.05, respectively, n = 5, P = 
0.13) (Figure 4.1). 
Histological examination of hoof sections from horses with chronic laminitis 
displayed characteristic histopathology of laminitis with mild to severe alterations to 
the lamellar architecture of the hoof, which were related to chronicity (r = 0.95, P = 
0.01) (Figure 4.2a-f). Mild changes were characterised by lengthening of the primary 
epidermal lamellae (PEL), attenuation and tapering of the tips of secondary 
epidermal lamellae (SEL) and the presence of abnormal columns of partially 
keratinised cells on either side of the keratinised axis of the PEL (Figure 4.2b and c 
and Figure 4.3). Moderate changes included marked straightening and elongation of 
the SEL (Figure 4.2d). Severe changes comprised complete loss of lamellar 
architecture, with epidermal cells forming a mass on either side of the PEL 
keratinised axis instead of being organised into recognisable SEL rows (Figure 4.2e 
and f). Histological sections from normal horses had no evidence of lamellar 
pathology (Figure 4.2a). 
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Examination of DRG sections, revealed a mild, generalised, reduction in 
organisation of neurons in C8 dorsal root ganglia of horses with laminitis compared 
with non-laminitic horses (Figure 4.4). In one horse with laminitis of 1 month’s 
duration, there was a decrease in the proportion of large size neurons in the C8 DRG 
compared to normal horses (5.7% vs. 20.4 ± 3.1%; n = 5) and, to a lesser degree, in 
the C4 DRG (5.8% vs. 16.6 ± 8.2%; n = 5), but this reduction was not present in 
other laminitic cases. 
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Figure 4.1. Thickness of the tunica media expressed as ratio of overall vessel 
thickness in the palmar digital artery and vein of normal and chronic laminitic 
horses. A significant reduction in the thickness of the tunica media in the palmar 
digital vein of horses with laminitis compared to unaffected horses was noted. No 
difference was observed in the palmar digital artery of horses with laminitis and 
normal horses. Histogram represents means ± SD, n = 5, * P < 0.05. 
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Figure 4.2. Lamellar sections (hoof) of a normal horse (a) and horses with chronic 
laminitis (b-e) (H&E). Sections show (a) normal lamellar architecture with 
symmetrical secondary epidermal lamellae (SEL) (asterisk) of equal size with 
rounded tips, (b and c) presence of SEL (asterisk) of uneven length with tapered tips 
and abnormal columns of partially keratinised cells on either side of the primary 
epidermal lamellae (PEL) axis (clinical signs 1 month duration), (d) attenuation of 
the SEL (asterisk) with marked straightening and elongation (clinical signs 8 months 
duration), and (e and f) loss of lamellar architecture with epidermal basal cells 
forming a contiguous mass (asterisk) on either side of the PEL keratinized axis 
(clinical signs 10 and 15 months duration, respectively). 
 
 
 
 
Figure 4.3. Full length PEL from lamellar sections (hoof) of a normal horse (top) and 
a horse with chronic laminitis (clinical signs 1 month duration) (bottom) (H&E). The 
PEL from the hoof section of the chronic laminitic horse showed marked lengthening 
compared to the PEL from the hoof section of the normal horse. (reconstituted) 
 
 
 
119 
 
 
 
 
 
 
 
 
Figure 4.4. C8 DRG sections of a normal horse (a) and a horse with chronic laminitis 
(b). In the C8 DRG section of the laminitic case (b) there appeared to be a mild, 
generalised, reduction in organisation of neurons compared to the non-laminitic C8 
DRG (a). 
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4.3.2 P2X1-3, 7 receptor subtype immunohistochemical analysis 
 
Immunohistochemical analysis of the palmar digital vessels in chronic 
laminitic horses revealed expression of P2X3 receptor subtype in smooth muscle 
cells of the tunica media in the palmar digital artery of horses with laminitis, which 
was absent from normal horses (Figure 4.5a and c). No differences were observed 
between the laminitic and normal horses in P2X3 receptor subtype distribution in the 
palmar digital vein (Figure 4.5b and d) or P2X1, 2 and 7 receptor subtypes in the 
palmar digital artery or vein. 
In the hooves of laminitic horses, expression of P2X1-3 and 7 receptor 
subtypes was evident in the proliferating, partially keratinised, epidermal cells 
adjacent to the PEL keratinised axis, which are not present in normal hooves. P2X7 
receptor subtype, in particular, appeared to have the strongest immunostaining 
(Figure 4.6). The basal epidermal cells in laminitic hooves retained the P2X1-3 and 7 
receptor subtype expression observed in normal horses and there were no differences 
in receptor subtype distribution or intensity in this layer between normal and chronic 
laminitic horses. 
In nervous tissue, no alterations were noted in the pattern of distribution of 
P2X1-3, 7 receptor subtypes in neuronal cell bodies or glial cells in the C4 or C8 
DRG, or spinal cord segments, between laminitic and normal horses. However, there 
were alterations in staining intensity for P2X3 receptor subtype in the C8 DRG, but 
not the C4 DRG, of two horses with laminitis of 1 month’s duration. In one case, a 
marked increase in the intensity of staining for P2X3 receptor subtype was evident in 
large neurons, coinciding with a mild reduction in the proportion of large neurons 
(Figure 4.7). In the other case, there was a small decrease in the intensity of staining 
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for P2X3 receptor subtype in all neurons, without any alterations in the proportions 
of the different sizes of neurons. In horses with laminitis of 8, 10 and 15 months’ 
duration, there were no differences in staining intensity for P2X3 receptor subtype in 
the C8 or C4 DRG compared to normal horses. No alteration in P2X7 staining 
intensity in Schwann cells was noted in the DRG of laminitic horses compared to 
normal horses. 
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Figure 4.5. P2X3 receptor subtype distribution in the palmar digital artery (a and c) 
and vein (b and d) of normal (a and b) and laminitic horses (c and d). P2X3 receptor 
subtype was absent in smooth muscle cells of the palmar digital artery in normal 
horses (a), whereas it was evident in palmar digital artery smooth muscle cells in 
laminitic horses (c). No change in P2X3 receptor subtype distribution was noted in 
the palmar digital vein between normal and laminitic horses (b and d, respectively). 
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Figure 4.6. P2X7 receptor subtype expression in the hoof of a normal (a) and a 
laminitic horse (b). Expression of P2X7 receptor subtype was evident in the 
proliferating, partially keratinised, epidermal cells adjacent to the PEL keratinised 
axis in the hoof of the laminitic horse (b, asterisks) which are absent in the hooves of 
normal horses (a). No change in receptor distribution in the basal epidermal cells was 
noted between the laminitic and normal horses. 
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Figure 4.7. (a-c) Surface plots for P2X3 receptor subtype staining intensity and 
proportion of small (a), medium (b) and large-size neurons (c) in C8 DRG of horses 
with chronic laminitis (n = 5). Staining intensity in C8 DRG for each laminitic case 
was normalised against the staining intensity in the C4 DRG of the same horse and 
expressed as a ratio to the average normalised staining intensity of the C8 DRG in 
five non-laminitic horses. In grey scale measurements, high values (orange) 
indicate low staining intensity, whereas low values (blue) indicate high staining 
intensity. In one horse with chronic laminitis of 1 month’s duration, there was a mild 
decrease in intensity of staining for P2X3 receptor subtype in small (a) medium-size 
(b) and large (c) neurons. In another horse with chronic laminitis of 1 month’s 
duration, there was a marked increase in intensity of staining for P2X3 receptor 
subtype, which coincided with a decrease in the proportion of large neurons in the 
DRG. (d and e) Representative photos of P2X3 receptor subtype immunostaining in 
the C8 DRG of a normal (d) and a laminitic (e) horse. 
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4.4 Discussion 
 
The distribution of purinergic P2X receptor subtypes in the horse has 
received little attention until recently (Zamboulis et al. 2013, Zerpa et al. 2013). 
However, since P2X receptors are involved in a diverse range of tissue functions 
including regulation of vascular tone, tissue sensitisation and chronic pain (Neary et 
al. 1996, Gu & Heft 2004, Chessell et al. 2005, Burnstock & Verkratsky 2010), they 
may have relevance in diseases such as equine laminitis. Here, P2X receptor subtype 
distribution was assessed in tissues likely to be affected by laminitis, such as the 
palmar digital vessels and nerve, dorsal root ganglia and spinal cord. 
 
Morphometric histological examination of the palmar digital vessels revealed 
a reduction in the thickness of the tunica media of the palmar digital veins in horses 
with laminitis compared to unaffected horses. Vascular events are considered to be 
important in the pathogenesis of equine laminitis (Peroni et al. 2006, Menzies-Gow 
et al. 2008) and in chronic laminitis, venograms show filling-defects, consistent with 
vascular compression (Baldwin & Pollitt 2010). Vascular remodelling (including 
thinning of the vessel wall) has been noted in chronic conditions with hyperdynamic 
circulation, such as cirrhosis (Fernandez-Varo et al. 2003), where chronic shear-
stress forces result in increases in endothelium-derived nitric oxide. Short-term 
vascular tone but also long-term vascular remodelling regulation is associated with 
purinergic signalling with a widespread expression of P2X receptors in vessels 
(Burnstock 2009, Ralevic 2012). In addition, ATP released in response to local 
hypoxia and changes in blood flow (shear stress) regulates digital constriction (Bodin 
et al. 1991, Bergfeld & Forrester 1992). 
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In the horse, Zerpa et al. (2013) demonstrated that digital vessels are 
responsive to purine agonists. Here, P2X3 receptor subtype was expressed in smooth 
muscle cells in the tunica media of the palmar digital artery of horses with laminitis 
but not in normal horses. In contrast, P2X1, 2 and 7 receptor subtypes were 
expressed in the palmar digital vessels of horses with and without laminitis. In other 
species, P2X3 receptors in blood vessels appear to have a role in neurogenic 
regulation of vascular tone and P2X3 channel is also involved in nociception in 
vascular disease (Erlinge & Burnstock 2008, Ralevic 2009). In addition, regulation 
of vascular tone by ET-1 may involve purinergic receptors (Joseph et al. 2013) and 
ET-1 may play a role in laminitis (Keen et al. 2008, Gauff et al. 2013). 
 
In this study, histological changes in the hooves of horses with chronic 
laminitis were similar to previous descriptions (Collins et al. 2010b, Hampson et al. 
2012) with lengthening of the PEL, attenuation and tapering of the tips of SEL and 
the presence of abnormal columns of partially keratinised cells on either side of the 
keratinised axis of the PEL to marked straightening and elongation of the SEL and 
complete loss of lamellar architecture with fusion of SEL in a contiguous mass. In 
addition, the severity of the observed histological changes was found to be correlated 
to the duration of laminitis of each case. 
In horses with laminitis, expression of P2X1-3 and 7 receptor subtypes was 
retained in basal epidermal cells and was also evident in partially keratinised cells; in 
particular, strong expression of P2X7 receptor subtype was noted in these cells. 
P2X7 receptor subtype has been co-localised with apoptotic markers and is involved 
in terminal differentiation in human epidermal keratinocytes (Greig et al. 2003). In 
addition, an increased rate of apoptosis has been demonstrated in epidermal lamellae 
127 
in the hooves of horses with laminitis (Faleiros et al. 2004, Asplin et al. 2010). 
 
Purinergic receptor expression and function in nervous tissue has received 
considerable attention, particularly in relation to nerve-tissue injury models and 
neuronal plasticity (Gu & Heft 2004, Chessell et al. 2005). In horses suffering from 
chronic laminitis, palmar digital nerve injury with abnormal morphology has been 
shown to occur followed by phenotypic changes in primary sensory neurons in C8 
DRG (fore limb) which are associated with neuropathic pain (Jones et al. 2007). In 
this study, the examined palmar digital nerve sections of normal and chronic 
laminitic horses were stained with H&E which did not allow for the identification of 
abnormal morphology and no change in P2X1-3 and 7 receptor subtype distribution 
and expression was observed. However, variable alterations in P2X3 receptor 
subtype immunostaining in C8 DRG (involved in innervation of the hoof) were noted 
in two horses with chronic laminitis of 1 month’s duration, but not in the C4 DRG 
(not involved in hoof innervation). In one case, there was a marked increase in 
staining of large neurons, which occurred in conjunction with a decrease in the 
proportion of these neurons. In the other case, there was a mild decrease in staining 
intensity in all neurons, independent of size; in this case there was no apparent 
alteration in the proportion of neurons of different sizes. Changes in P2X3 receptor 
subtype expression were not detected in the DRG of horses with chronic laminitis of 
longer duration. 
Temporal expression of the P2X3 receptor subtype has been described in 
rodents with P2X3 receptor subtype showing involvement in the induction and early 
maintenance of long lasting pain rather than in the later phase (Nakagawa et al. 
2007). Maintenance of P2X3 receptor subtype expression in large neurons is thought 
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to mediate mechanical allodynia, i.e. a painful response to a normally innocuous 
mechanical stimulus, in rats (Kage et al. 2002). Evaluation of DRG in additional 
cases of equine laminitis in the early stages of chronic disease (1 month’s duration) 
may support this observation. 
P2X7 receptor has also an important role in neuropathic pain and has been 
shown to be upregulated in human DRG and injured nerves from chronic neuropathic 
pain patients (Chessell et al. 2005). Here, such changes in P2X7 receptor subtype 
expression were not noted in DRG from chronic laminitic horses. 
 
 In this chapter, the examination of DRGs from horses suffering from chronic 
laminitic pain revealed temporal expression of the P2X3 receptor subtype protein in 
DRG neurons. Although the findings presented here are descriptive due to the 
restricted availability of samples, they provide ground for further research in this 
direction. Examination of more samples could help establish a temporal pattern of 
purinergic expression in DRG neurons of laminitic horses and reveal potential targets 
for drug development. Furthermore, immunohistochemical analysis of the palmar 
digital vessels and the hoof also showed altered purinergic expression. The changes 
in purinergic expression observed in these tissues could be a result of adaptive 
mechanisms responding to lamellar changes occuring in laminitis or part of an 
ongoing pathology due continuous exposure to the inciting cause (e.g. 
endocrinopathic laminitis). It would therefore be interesting for future work to 
define, in addition to chronicity, the cause of laminitis in the sampled cases to allow 
for better understanding of purinergic involvement in the observed lamellar 
pathology. 
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Chapter 5 
 
Expression of functional P2X receptors in equine 
nervous tissue 
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5.1 Introduction 
 
P2X receptors are involved in many cellular functions and can be altered in 
pathological conditions. Understanding of their function and properties is therefore 
important to elucidate their role in pathological conditions and their pharmacological 
characterisation is required to open the way for development of new drugs. 
The patch-clamp technique is the gold standard technolgy for studying ion 
channel pharmacology and has been widely used in the characterisation of P2X 
receptors. Additionally, intracellular calcium measurements have also been used for 
the characterisation of P2X receptors’ pharmacological properties with the advantage 
of allowing a higher throughput for the characterisation (He et al. 2003, Calvert & 
Evans 2004). 
In Chapter 3, P2X1-7 receptor mRNA signal was identified in equine tissue 
and P2X1-3 and 7 receptor subtype distribution was detailed in the same tissues 
using immunohistochemical methods. However, evidence for P2X receptor mRNA 
or the observed P2X receptor immunoreactivity does not necessarily indicate the 
presence of functional receptors. Furthermore, the co-localisation of P2X1-3 and 7 
receptor proteins in equine neurons raised the possibility of multiple subtype 
expression. The aim of this chapter was to investigate the functionality of the 
expressed P2X receptors in equine nervous tissue and characterise them 
pharmacologically. For this purpose, electrophysiolgy and intracellular calcium 
measuring and imaging methods were used. 
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5.2 Study design 
 
• Sample collection – C4 and C8 DRG and spinal cord segments were 
dissected from normal horses and cells were extracted with enzymatic 
digestion of the tissues with collagenase I (2 mg/mL) and dispase II (5 
mg/mL). Extracted cells were used for experiments freshly isolated or 
following culture (see 2.5.1 Tissue digestion and neurons extraction p.62). 
 
• Whole-cell and perforated whole-cell patch-clamping experiments – 
Whole-cell and perforated whole-cell patch-clamping experiments were 
performed on freshly isolated C4 and C8 DRG neurons. Neurons were plated 
at high density in poly-lysine coated glass bottom Petri dishes and P2X 
receptor agonists were applied with a U-tube delivery system. P2X receptor 
antagonists were perfused in the Petri dish waterbath. For the perforated 
whole-cell patch-clamp technique, an amphotericin B solution (210 µg/mL) 
was used as a pore-forming agent for the internal pipette solution. Recordings 
were made with the cells held at -60 mV (see 2.5 Electrophysiology 
experiments p.62). 
 
• Intracellular calcium measurements, fluorescence plate reader – 
Intracellular calcium measurements conducted in the fluorescence plate 
reader were carried out in C8 DRG cells cultured to confluence. After culture, 
the DRG cell population was mainly consisting of supportive cells, ie. 
satellite glial cells, Schwann cells, and fibroblasts, and few or no neurons (see 
2.6.1 Cells p.69). For the measurements, Fura-2 AM, a UV excitable 
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ratiometric fluorescent dye with excitation peaks of 340 nm (Ca2+-bound dye) 
and 380 nm (Ca2+-free dye) and an emission peak of 510 nm, was used. The 
cells were incubated with 6 µM of Fura-2 AM to load the dye and used at a 
density of 250,000 cells/mL. The potent P2X7 agonist BzATP and the non-
selective P2X antagonist iso-PPADS were used to challenge the cells and 
single F340 and F380 fluorescence measurements were taken from the wells 
before and straight after the addition of BzATP (10, 50, 100, 500 µM and 1 
mM) (added once) with and without pre-incubation of the cells with iso-
PPADS. The fluorescence ratios F340/F380 were calculated and changes in 
fluorescence were expressed as percent changes versus baseline fluorescence 
(fluorescence before application of agonists) (see 2.6.3 Fluorescence plate 
reader recordings p.73). 
 
• Intracellular calcium measurements, spectrofluorimeter – Intracellular 
calcium measurements were carried out in C8 DRG cells cultured to 
confluence and freshly isolated C8 spinal cord segment cells. For the 
measurements, Fura-2 AM was loaded into the cells with a 6 µM Fura-2 AM 
solution and cells were used at a density of 500,000 cells/mL. P2X agonists 
and antagonists used to challenge the cells are summarised in Table 5.1. 
Fluorescence was measured in resting cells to establish the signal baseline 
and signal recordings were taken after agonist application for periods of 300 
seconds, with intervals of 2-3 seconds for the first 30 seconds (0-30 seconds), 
10 seconds for the next 150 seconds (30-180 seconds), and 30 seconds for the 
last 120 seconds (180-300 seconds). Measurements were also carried out as 
mentioned above in calcium free buffer after stimulation with 5 µM of 
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BzATP (cultured C8 DRG cells, added once) for 120 seconds (see 2.6.4 
Spectrofluorimeter recordings p.74). Fluorescence values were corrected for 
background fluorescence and the F340/F380 fluorescence ratios, reflecting 
[Ca2+]i concentrations, were calculated. F340/F380 fluorescence ratios 
following agonist addition were expressed in graphs corrected for baseline 
signal and maximum fold or percent changes in Fura-2 fluorescence (versus 
baseline F340/F380) were calculated for all used P2X agonists and antagonists. 
For P2X antagonists, the percent of inhibition was also calculated (see 2.6.5 
Data analysis p.75). 
 
 
Table 5.1. P2X agonists and antagonists used in intracellular calcium measurements 
carried out in the spectrofluorimeter, concentrations and tested cells. 
P2X agonist/antagonist Concentration (µΜ) Cells  
ATP P2X agonist 5, 10, 50, 100, 200, 500 spinal cord cells n=1 
BzATP potent P2X7 agonist 0.5 , 5, 50 cultured DRG cells n=1 
  10, 50, 100, 200 cultured DRG cells n=3 
iso-PPADS non-selective P2X antagonist 20 cultured DRG cells n=3 
BBG P2X7 selective antagonist 1000 cultured DRG cells n=3 
The use of P2X antagonists was combined with stimulation of the cells with 100 µM BzATP. 
 
 
• Intracellular calcium imaging – Intracellular calcium imaging experiments 
were carried out in freshly isolated C8 DRG cells with Fluo-4 AM, a single 
wavelength dye with an excitation peak of 494 nm and an emission peak of 
506 nm. Cells were loaded with a 5-10 µΜ Fluo-4 AM solution and 
challenged with ATP (1 mM) (added once). A photo of the cells in a resting 
state was acquired before addition of the agonist and after addition of the 
agonist, photos of the stimulated cells were taken every 2 seconds for 60 
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seconds. Neuron cells were identified based on size and fluorescence 
intensity in stimulated neurons was measured and corrected for background 
fluorescence. Changes to fluorescence 30 seconds after agonist application 
were calculated versus baseline fluorescence in resting cells (see 2.7 
Intracellular calcium imaging p.76). 
 
• Statistical analysis – Where applicable, the mean and standard deviation 
were calculated and data were presented as mean ± SD. Data were checked 
for Normality using the Shapiro-Wilk test and significant differences were 
determined with Student’s t test. The level of significance was set at P < 0.05 
(see 2.8 Statistical analysis p.79). 
 
 
5.3 Results 
 
5.3.1 Electrophysiology experiments 
 
Good quality, stable gigaseals were consistently achieved in the extracted 
DRG neurons and whole-cell configuration was achieved on a few occasions both 
with the whole-cell and the perforated whole-cell techniques. However, the quality of 
the cell or the clamp at each time did not allow for recordings to be made in either 
whole-cell or perforated whole-cell patch-clamp. 
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5.3.2 Intracellular calcium measuring experiments 
 
5.3.2.1 Fluorescence plate reader 
 
Monitoring of intracellular calcium ([Ca2+]i) in Fura-2-loaded cultured equine 
C8 DRG cells with the fluorescence plate reader showed an increase in [Ca2+]i levels 
after application of P2X7 potent agonist BzATP to the cells. Specifically, application 
of 10, 50, 100 and 500 µM of BzATP to the cell suspension was followed by an 
increase in the recorded F340/F380, reflecting an increase in [Ca2+]i levels, whereas 
application of 1 mM of BzATP resulted in a decrease of F340/F380. Incubation of the 
cell suspensions with the non-selective antagonist iso-PPADS (20 µM) before the 
application of BzATP caused a decrease of the [Ca2+]i increase observed in BzATP 
stimulated cells for BzATP concentrations of 50, 100 and 500 µM. Application of 10 
µM BzATP to iso-PPADS-preincubated cells caused an increase in [Ca2+]i levels 
greater than the one recorded in cells without iso-PPADS. Finally, application of 1 
mM BzATP to iso-PPADS-preincubated cells resulted in an increase in [Ca2+]i levels 
compared to the decrease observed in cells without iso-PPADS (Figure 5.1). 
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Figure 5.1. Percent changes in F340/F380 values for Fura-2-loaded cultured equine C8 
DRG cells challenged with P2X7 potent agonist BzATP with (red) and without 
(blue) pre-incubation with the non-selective P2X antagonist iso-PPADS (20 µM). 
BzATP was used at concentrations of 10, 50, 100, and 500 µM, and 1 mM (n = 1). 
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5.3.2.2 Spectrofluorimeter 
 
In equine DRG cells, mostly comprised of non-neuronal cells, application of 
P2X7 receptor potent agonist BzATP resulted in a marked and reproducible increase 
in [Ca2+]i levels. The observed increase in [Ca2+]i levels was concentration-dependent 
for BzATP concentrations of 10, 50, and 100 µM (n = 3) with 1.27, 1.62, and 2.61-
fold changes in F340/F380 fluorescence ratio. However, stimulation with 200 µM of 
BzATP resulted in a 1.30-fold change in F340/F380 which was lower than the ones 
observed with lower BzATP concentrations (Figure 5.2, Table 5.2). Preliminary data 
with stimulation with 0.5, 5 and 50 µM also displayed a concentration-dependent 
increase in [Ca2+]i levels with 1.47, 1.41 and 1.84-fold changes in F340/F380. In Ca2+-
free medium, BzATP (5 µM) failed to elicit an [Ca2+]i increase supporting the 
expression of functional P2X receptors in DRG non-neuronal cells, since only 
activated P2X receptors cause calcium influx while activated P2Y receptors cause 
calcium release from intracellular stores (Idzko et al. 2001). To further confirm the 
observed rise in [Ca2+]i levels was mediated by P2X receptors and more specifically 
P2X7 receptors, the non-selective P2X antagonist iso-PPADS and the selective P2X7 
receptor antagonist BBG were used. [Ca2+]i responses evoked by 100 µM BzATP 
were partially inhibited by 20 µM iso-PPADS with 51.0% inhibition and 1 mM BBG 
with 23.0% inhibition (Table 5.2, Figure 5.3). 
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Figure 5.2. F340/F380 fluorescence ratios for equine DRG non neuronal cells 
stimulated with 10, 50, 100, and 200 µM BzATP (normalised for their respective 
basal fluorescence) (n = 3). 
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Table 5.2. Maximum fold changes in Fura-2 fluorescence (F340/F380 fluorescence 
ratios) in DRG non-neuronal cells in response to BzATP, iso-PPADS and BBG 
versus basal fluorescence. Where applicable data is presented as mean ± SD, n = 3,   
* P < 0.05. 
Agonist and antagonist 
concentrations 
F340/F380 maximum fold change 
(versus basal fluorescence) 
 
10 µM BzATP 1.26 ± 0.08 *  
50 µM BzATP 1.62 ± 0.50  
100 µM BzATP 2.61 ± 0.62  
200 µM BzATP 1.30 ± 0.08 *  
5 µM BzATP in Ca2+-free 
solution 
0.94  
iso-PPADS (20 µM) + 100 
µM BzATP 
1.28 ± 0.02 51.0 % inhibition 
BBG (1mM) + 100 µM 
BzATP 
2.01 ± 0.10 23.0 % inhibition 
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Figure 5.3. Maximum percent changes in Fura-2 fluorescence (F340/F380 fluorescence 
ratios) in DRG non-neuronal cells in response to BzATP, iso-PPADS and BBG 
versus basal fluorescence. Where applicable the histogram represents mean ± SD,   
(n = 3, Ca2+-free + 5 µM BzATP n = 1), * P < 0.05. 
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In equine spinal cord cells, ATP induced an increase in [Ca2+]i displaying a 
biphasic [Ca2+]i response consisting of an initial transient peak within 30 seconds of 
agonist stimulation and a sustained component maintained until the end of 
measurements at 300 seconds. For lower ATP concentrations of 10 and 50 µM the 
initial transient peak displayed a concentration-depedent response with F340/F380 
maximum fold-changes of 1.25 and 1.40, respectively, followed by a sustained 
response which was closer to basal fluorescence (Table 5.3, Figure 5.4 and 5.7). 
Higher ATP concentrations of 100, 200 and 500 µM elicited the same biphasic 
[Ca2+]i response but with a smaller initial peak. The sustained phase showed similar 
[Ca2+]i levels to the ones seen with lower ATP concentrations (Figure 5.5). The 
maximum fold changes in F340/F380 observed for these concentrations were 1.25, 
1.24 and 1.30, respectively, and were noted in the sustained phase of the [Ca2+]i 
repsonse with the exception of the 1.24-fold change for 200 µM ATP which was 
noted in the initial transient peak (Table 5.3, Figure 5.6). 
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Figure 5.4. F340/F380 fluorescence ratios for equine spinal cord cells stimulated with 
10 and 50 µM ATP (normalised for their respective basal fluorescence) (n = 1). 
 
 
 
 
Figure 5.5. F340/F380 fluorescence ratios for equine spinal cord cells stimulated with 
100, 200 and 500 µM ATP (normalised for their respective basal fluorescence)        
(n = 1). 
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Table 5.3. Maximum fold changes in Fura-2 fluorescence (F340/F380 fluorescence 
ratios) in equine spinal cord cells in response to ATP versus basal fluorescence        
(n = 1). 
ATP concentration F340/F380 maximum fold change 
(versus basal fluorescence) 
10 µM 1.25 
50 µM 1.40 
100 µM 1.25 
200 µM 1.24 
500 µM 1.30 
 
 
 
 
 
Figure 5.6. Maximum percent changes in Fura-2 fluorescence (F340/F380 fluorescence 
ratios) in spinal cord cells stimulated with 10, 50, 100, 200 and 500 µM ATP versus 
basal fluorescence (n = 1). 
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5.3.3 Intracellular calcium imaging experiments 
 
Loading of equine DRG cells with Fluo4-AM was not consistently successful 
and only one series of measurements was achieved after agonist stimulation. More 
specifically, application of 1 mM of ATP elicited an increase in fluorescence ratio 
(F490/F0, where F0 is the background fluorescence) in all tested DRG neurons          
(n = 19) with a mean ΔF490/F0, of 0.045 (SD=0.03, range 0.005 – 0.102) after 30 
seconds of exposure (Figure 5.7). 
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Figure 5.7. Fluo4-AM calcium imaging in DRG neurons in (a) a resting state and (b) 
30 seconds after application of 1 mM of ATP (fluorescence artificially enhanced for 
display purpose). 
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5.4 Discussion 
 
In Chapter 3, the presence of P2X receptor proteins in equine tissues was 
demonstrated. In this chapter, intracellular calcium measurements and 
electrophysiology were used to investigate the functionality of the expressed P2X 
receptors in equine nervous tissue. The use of P2X agonists in intracellular calcium 
measurements elicited an [Ca2+]i response which was partially inhibited by P2X 
antagonists providing evidence for the presence of functional purinergic receptors in 
equine DRG and spinal cord cells. 
 
Application of P2X7 receptor potent agonist BzATP and ATP in equine DRG 
non-neuronal cells and spinal cord cells, respectively, caused a marked and 
reproducible increase of free [Ca2+]i supporting the presence of functional P2X and 
purinergic receptors, respectively, in these cells. Stimulation of the cells with 
different agonist concentrations showed a concentration-dependent pattern in [Ca2+]i 
responses both for ATP and BzATP. Interestingly, agonist concentrations of 200 µM 
BzATP and 100 µM ATP or greater produced an [Ca2+]i rise of smaller magnitude 
than lower concentrations. Similar findings are reported in eosinophils and astroglial 
cells with 1 mM of ATP and BzATP, showing similar or smaller [Ca2+]i changes 
compared to 100 µM, whereas a clear increase in the magnitude of [Ca2+]i responses 
is noted between concentrations of 10 µM and 100 µM of the same agonists (Idzko et 
al. 2001, Hamilton et al. 2008). The decreased response observed with higher 
concentrations of ATP may be due to cell death following P2X7 receptor activation 
(Luo et al. 2013). Also, in DRG non-neuronal cells, prolonged BzATP stimulation 
evoked a gradually increasing long lasting response, whereas upon prolonged ATP 
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stimulation spinal cord cells displayed a biphasic [Ca2+]i response consisting of a 
rapid peak followed by a sustained elevation. In the ATP-stimulated biphasic 
response, the two phases displayed distinct characteristics with the transient phase 
showing changes in magnitude according to the agonist concentration and the 
sustained phase showing similar magnitude for all concentrations. The biphasic 
pattern in ATP-stimulated [Ca2+]i responses has been previously reported and has 
been attributed to presence of heterogenous populations of purinergic receptors, 
where P2Y receptors would appear to mediate the transient phase and P2X, including 
P2X7, receptors the sustained phase (White et al. 2001, Nobile et al. 2003, Gifford et 
al. 2004, Weng et al. 2008). 
In DRG non-neuronal cells, mediation of [Ca2+]i responses by P2X receptors 
was coroborrated by the abolition of the observed [Ca2+]i responses in Ca2+-free 
media, as P2X receptors depend on extracellular Ca2+ influx whereas P2Y receptors 
regulate Ca2+ mobilisation from intracellular stores (Idzko et al. 2001). Additional 
measurements with preincubation of DRG non-neuronal cells with the non-selective 
P2X receptor antagonist iso-PPADS (20 µM) and the selective P2X7 receptor 
antagonist BBG (1 mM) resulted in partial inhibition of [Ca2+]i responses to BzATP 
(100 µM) (51.0% and 23.0% respectively), further confirming the expression of 
functional P2X receptors, including P2X7 receptors, in equine DRG non-neuronal 
cells. Partial inhibition of [Ca2+]i responses by the antagonists could be due to 
insufficient preincubation (10 minutes), or insufficient antagonist concentration, as 
antagonist potency is greatly affected by preincubation time and antagonist 
concentration, especially across species (North 2002). In rat cortical astrocytes, 50 
µM iso-PPADS with 15 minutes of preincubation was used to achieve 65% 
inhibition of the effect of 100 µM ΒzATP (Jacques-Silva et al. 2004). Also, although 
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iso-PPADS is referred to as a P2X antagonist, data about its potency against P2X7 
receptors is equivocal and species-dependent (North 2002, Jacques-Silva et al. 2004). 
BBG is a P2X7 receptor selective antagonist effective in the nanomollar range but 
concentrations of 10 mM have also been used (Jiang et al. 2000, Noguchi et al. 
2008). Here, BBG results confirmed that BzATP acted on functional P2X7 receptors 
in equine DRG cells. However, persistence of part of the BzATP-stimulated response 
after BBG preincubation could be attributed to, except for insufficient preincubation 
and antagonist concentration, the presence of functional P2X receptors other than 
P2X7 receptors. Although BzATP has been widely used as a selective P2X7 receptor 
agonist (Idzko et al. 2001), it is not as it has been documented to have agonistic 
effects on other P2X receptors as well as P2Y receptors (Fischer et al. 2001, North et 
al. 2002, Zhang et al. 2005). 
 
Spectrofluorimeters have been widely used for intracellular calcium 
measurements, their main disadvantage however being the requirements in cell 
numbers. When using freshly isolated DRG cells the number of available cells is 
limited and do not allow for many sets of measurements. An alternative to the use of 
the spectrofluorimeter is the use of a plate reader for intracellular calcium 
measurements which has lower requirements in cell numbers. In this study, 
intracellular calcium measurements carried out in a plate reader with application of 
P2X7 potent agonist BzATP produced an increase in DRG non-neuronal cells [Ca2+]i 
levels. This gave an indication for the presence of functional P2X7 receptors in 
equine DRG non-neuronal cells. However, the time required for the plate reader to 
go through all the wells resulted in measurements being taken at slightly different 
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timepoints for each well and did not allow for a close and accurate monitoring of 
[Ca2+]i levels through time. 
 
Calcium imaging experiments with Fluo4-AM were chosen for their smaller 
requirement in cell numbers compared to spectrophotometric calcium measurements 
and because they allowed for differentiation of DRG neurons and non-neuronal cells 
when measuring the elicited [Ca2+]i-responses. Fluo-4 AM has been used for calcium 
imaging in neurons (Hegg et al. 2003, Hung et al. 2010), although unsuccessful 
loading of neurons has also been reported (Newman 2001, Weick et al. 2003). Here, 
loading of C8 DRG neurons with the dye was not consistently successful and only 
one series of measurements was possible. In these measurements, stimulation with 1 
mM ATP evoked an [Ca2+]i-rise of ranging amplitude in DRG neurons providing 
evidence for the presence of functional purinergic receptors in equine DRG neurons. 
 
Electrophysiological methods have been most commonly used for the 
identification of functional P2X receptors and their pharmacological characterisation 
(Khakh et al. 1995, Bianchi et al 1999). Moreover, electrophysiology has proven a 
useful tool in the linking of P2X receptor phenotypic changes to functional changes 
and in the determination of the role of P2X receptors under injurious conditions (Xu 
& Huang 2002, Pan et al. 2009). Here, whole-cell and perforated whole-cell patch-
clamp were used to study the functional properties of P2X receptors in equine DRG. 
Good quality whole-cell configurations, however, could not be achieved due to a 
combination of inexperience in electrophysiology techniques and equine DRG tissue 
limitations for cell extraction. To overcome tissue limitation issues future work could 
include the establishment of an equine neuron cell line. An equine neuron cell line 
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would provide a continuous source of cells and allow optimisation of the whole-cell 
patch-clamp technique to achieve whole-cell configurations. 
 
A number of limitations were present in this set of experiments starting with 
limited availability of tissue for cell extraction. Also, equipment and time restrictions 
contributed to the difficulties faced in this chapter. However, intracellular calcium 
measurements with the spectrofluorimeter gave consistent and reliable results 
providing evidence for the presence of functional purinergic and P2X receptors in 
equine spinal cord and DRG cells, respectively. Future work with measurements on 
additional cells with different P2X agonists and antagonists could provide more 
details about the receptors expressed in these cells. Furthermore, the establishment of 
an equine neuron cell line would provide the required cell numbers to test additional 
P2X agonists and antagonists. 
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Chapter 6 
 
General discussion 
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Chronic pain in equine laminitis often leads to debilitation and euthanasia of 
the horse. It is a significant welfare issue for horses worldwide. Therefore, it is 
important to try to understand the molecular mechanisms in chronic laminitis pain 
pathways with the eventual aim to develop novel, targeted therapeutics to reduce 
morbidity and mortality. Furthermore, the mechanisms behind the development of 
laminitis have not been fully elucidated and research in this area would advance our 
understanding of laminitis. Purinergic P2X receptors have a pivotal role in pain 
pathways as well as regulation of vascular tone, cell differentiation and apoptosis, 
and other tissue functions relevant to laminitis but have, as yet, not been studied in 
detail in naturally occurring laminitis, where pain and tissue damage is such a central 
feature. 
In this study, the presence and distribution of P2X receptors in tissues of the 
equine digit and its associated vasculature and innervation was investigated in 
normal horses and horses suffering from naturally occurring chronic active lamintis. 
In addition the functionality of P2X receptors expressed in equine nervous tissue was 
investigated. 
 
 
6.1 Expression of purinergic P2X receptors in horses 
 
Purinergic P2X receptors are ubiquitous receptors and although they are 
involved in numerous physiological and pathological processes they have received 
little attention in the horse. Here, purinergic P2X receptors were identified in the 
equine hoof and its associated vasculature and innervation. Gene expression (mRNA) 
for all seven receptors and protein expression for P2X1-3 and 7 receptor subtype 
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proteins was found in the studied tissues. The expression of P2X receptor subtypes in 
a variety of equine tissues confirms the widespread expression of P2X receptors 
noted in other vertebrates and highlights the importance of understanding their role 
in cellular processes in the horse. 
Validation of antibodies for use in equine tissue, in this study, was only 
possible for P2X1-3 and 7 receptor subtype proteins, and future work should include 
testing of more P2X4-6 receptor subtype protein antibodies manufactured against 
different epitopes to enable the study of these receptor subtypes, too. Custom made 
antibodies against the equine P2X4-6 receptor protein amino acid sequences could 
also be used in case commercial antibodies were not successful. 
 
 
6.2 Expression and distribution of purinergic P2X receptors in normal and 
chronic laminitic horses 
 
Immunohistochemical analysis of P2X1-3 and 7 receptor subtypes 
distribution showed differential cellular distribution in equine tissue suggesting a 
subtype-specific regulation of functions in these tissues (Glass et al. 2000). Extension 
of these results in tissues from chronic laminitic horses demonstrated that distribution 
and expression of P2X1-3 and 7 receptor subtypes differed between normal and 
diseased tissues. Differential expression of P2X receptor subtypes in naturally 
occurring disease states in other species has been previously reported and supports a 
role for P2X receptors in pathological processes offering insights for disease 
regulation (review Burnstock & Kennedy 2011). 
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In this study, immunohistochemical analysis of equine nervous tissue 
revealed P2X3 receptor subtype was expressed solely in neuronal cells whereas 
P2X7 receptor subtype demonstrated strong expression in glial cells. This tissue-
specific distribution is also reported in other species and supports a special role for 
these receptors in nervous tissue physiology. More specifically, P2X3 receptor has a 
major role in nociception, both physiological and pathological whereas P2X7 
receptors in glial cells are involved in the induction and maintenance of 
inflammatory and neuropathic pain (Hughes et al. 2007, Wirkner et al. 2007). 
Expression of these two key receptors was therefore compared in C8 DRGs 
(innervating the forelimb) of normal horses and horses suffering from chronic 
laminitis revealing P2X3 receptor subtype expression was altered in horses with a 
shorter duration of chronic laminitis (1 month). In particular, one case presented a 
marked increase in immunostaining in large neurons which coincided with a decrease 
in the proportion of these neurons in the DRG. A temporal pattern in P2X expression 
in chronic pain has also been described in rodents with the participation of P2X3-
containing receptors in the induction and early maintenance of long-lasting pain but 
not the late phase (Nakagawa et al. 2007). 
Further investigation of changes occurring in the early maintenance of 
chronic pain in laminitis but also investigation of P2X receptors involvement in the 
later phase of chronic pain could therefore reveal new targets amongst P2X receptors 
for pain management. Future work with more DRG samples from horses suffering 
from chronic laminitis would help identify changes in P2X receptors expression 
which may be significant in neuropathic pain pathways. 
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P2X receptor subtypes’ widespread distribution in horses suggests a role in 
regulation of other functions in addition to pain pathways. In this study, horses 
suffering from chronic laminitis displayed expression of P2X3 receptor subtype in 
smooth muscle cells of the palmar digital artery which was absent in normal horses. 
In normal horses, P2X1-3 and 7 receptor subtype expression was identified in palmar 
digital vein smooth cells but P2X3 receptor subtype was absent from the palmar 
digital artery smooth muscle cells. Vascular events have a central role in the 
pathogenesis of laminitis but are also shown to persist in the chronic phase (Baldwin 
& Pollitt 2010). Additionally, in endocrinopathic laminitis, laminitis-inducing factors 
are ongoing and so may be vasoconstriction and vascular events. 
Here, morphometric analysis of equine digital vessels revealed a decrease in 
the thickness of the smooth muscle layer (tunica media) of palmar digital veins from 
chronic lamintic horses compared to normal horses, confirming the presence of 
vascular pathology in chronic laminitis. Further morphometric analysis of palmar 
digital vessel samples at different phases of lamintis may help understand if the 
observed changes here are part of the ongoing vascular pathology in laminitis or an 
adaptive change as a result of altered digital blood flow. Furthermore, P2X1-3 and 7 
have been found to participate in the regulation of vascular tone in the equine digital 
vessels (Zerpa et al. 2013). There is therefore evidence for the participation of P2X 
receptors in vascular regulation in horses and P2X3 receptor subtype expression in 
the palmar digital artery of horses with laminitis may develop in response to the 
occurring vascular events. 
 
Finally, in chronic laminitic hooves, P2X1-3 and 7 receptor subtypes were 
present in the basal epidermal cells, similarly to distribution in normal hooves, but 
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also in partially keratinised cells present in the lamellae of laminitic hooves, with 
particularly strong staining for P2X7 receptor subtype. P2X7 receptor is linked to 
apoptosis and is also known to participate in terminal differentiation in epidermal 
cells (Greig et al. 2003). Furthermore, in chronic laminitic hooves, epidermal cells 
demonstrate an increased apoptosis rate (Faleiros et al. 2004). P2X7 receptor subtype 
could therefore be involved in the regulation of apoptosis in basal epidermal cells 
and the dyskeratosis observed in chronic laminitic hooves. Further investigation of 
this hypothesis with co-localisation studies of apoptosis markers and P2X7 receptor 
subtype could provide insight in the mechanisms responsible for lamellar 
histopathology in chronic laminitis. 
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Table 6.1. Summary of P2X1-3 and 7 distribution in key equine tissues associated 
with laminitis in normal and chronic laminitic horses. 
P2X receptor subtype expression Tissue Cells 
Normal Chronic laminitic 
Palmar digital artery Endothelial cells P2X2  
 Smooth muscle cells P2X1, 2, 7 + P2X3 
Palmar digital vein Endothelial cells P2X2, 3  
 Smooth muscle cells P2X1-3, 7  
Palmar digital nerve Nerve fibres P2X1-3  
 Schwann cells P2X1, 2, 7  
Hoof Basal epidermal 
cells 
P2X1-3, 7 + partially 
keratinised basal 
epidermal cells 
DRG (C4, C8) Neurons P2X1-3 altered P2X3 
expression in C8 
DRG 
 Satellite glial cells P2X1, 2  
 Schwann cells P2X7  
Spinal cord (C4, C8) Neurons P2X1-3, 7  
 Glial cells P2X1, 2, 7  
 Ependymal cells P2X1-3, 7  
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6.3 Expression of functional purinergic P2X receptors in equine nervous tissue 
 
Despite the use of a number of techniques to investigate functional aspects of 
P2X receptors, limitations were present in this set of experiments. Due to the reliance 
of naturally occurring disease from a hospital population, there was often a limited 
availability of tissue for cell extraction. In addition, equipment and time restrictions 
contributed to the difficulties faced in this part of the project. However, it was 
possible to measure intracellular calcium using spectrofluorimetric methods and 
through the use of purinergic agonists and antagonists, this provided evidence for the 
presence of functional purinergic and P2X receptors in equine spinal cord and DRG 
cells. 
Further measurements using additional samples and refinement of techniques, 
particularly electrophysiological methods, could provide more details about the 
receptors expressed in these cells. For this purpose the establishment of an equine 
neuronal cell line might be beneficial, especially to address the limited availability of 
equine samples. 
 
 
6.4 General remarks 
 
The study of naturally occurring chronic active laminitis is necessary to be 
able to understand the mechanisms of disease and provide novel routes for 
therapeutic intervention, but provides significant challenges to the researcher. The 
use of naturally occurring models rather than induced disease models has to take into 
account the temporal nature of the condition, wide biological variation and limited 
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tissue availability. There are a number of models available for the induction of 
laminitis however they are undesirable for welfare reasons and are not available in 
the United Kingdom based on this fact. 
 
The expression of P2X receptor subtypes in key equine tissues associated 
with laminitis and its chronic pain state, the presence of alterations in their 
expression and distribution in laminitic tissues and their wide-range of physiological 
roles highlight an important avenue of hitherto underdeveloped research in this area. 
Further work to elucidate the involvement of P2X receptors in laminitis and 
associated chronic pain may help understand the mechanisms involved in its 
pathology and offer insights for disease modulation and pain management in chronic 
laminitis and other conditions of the horse associated with chronic pain. 
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